CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | irinotecan |
|
Accession: | CHEBI:80630
|
browse the term
|
Definition: | A member of the class of pyranoindolizinoquinolines that is the carbamate ester obtained by formal condensation of the carboxy group of [1,4'-bipiperidine]-1'-carboxylic acid with the phenolic hydroxy group of (4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2- hydrochloride]quinoline-3,14-dione. Used (in the form of its hydrochloride salt trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, which is ~1000 times more active. |
Synonyms: | exact_synonym: | (4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate |
| related_synonym: | Formula=C33H38N4O6; HSDB 7607; InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1; InChIKey=UWKQSNNFCGGAFS-XIFFEERXSA-N; Irinophore C; Irinotecan lactone; Irinotecan mylan; SMILES=C1(=CC=C2C(=C1)C(=C3C(=N2)C=4N(C3)C(C5=C(C4)[C@](C(OC5)=O)(CC)O)=O)CC)OC(=O)N6CCC(CC6)N7CCCCC7; irinotecanum |
| xref: | CAS:97682-44-5; DrugBank:DB00762; Drug_Central:1482; HMDB:HMDB0014900; KEGG:C16641; KEGG:D08086; LINCS:LSM-2167 |
| xref_mesh: | MESH:D000077146 |
| xref: | PDBeChem:CP0; PMID:26081596; PMID:26352218; PMID:26381420; PMID:26487578; PMID:26503200; PMID:26526067; PMID:26541586; PMID:26574999; PMID:26580826; PMID:26739304; Reaxys:4839096; Wikipedia:Irinotecan |
| cyclic_relationship: | is_conjugate_base_of CHEBI:90895 |
|
|
|
G |
A2m |
alpha-2-macroglobulin |
increases expression |
EXP |
Irinotecan results in increased expression of A2M mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:156,570,163...156,619,870
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases response to substance affects expression affects response to substance affects export affects metabolic processing |
ISO EXP |
ABCB1 exon SNP affects the susceptibility to and affects the metabolism of Irinotecan ABCB1 protein results in decreased susceptibility to Irinotecan Irinotecan affects the expression of ABCB1A mRNA ABCB1 gene polymorphism affects the susceptibility to Irinotecan ABCB1 protein affects the export of Irinotecan bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1A protein affects the metabolism of Irinotecan]; Everolimus inhibits the reaction [ABCB1A protein affects the metabolism of Irinotecan] ABCB1A gene mutant form results in decreased susceptibility to Irinotecan |
CTD |
PMID:12960109 PMID:15655543 PMID:15801936 PMID:16815871 PMID:20097248 PMID:24727322 PMID:32387182 More...
|
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
affects metabolic processing multiple interactions |
ISO |
ABCB1B protein affects the metabolism of Irinotecan bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1B protein affects the metabolism of Irinotecan]; Everolimus inhibits the reaction [ABCB1B protein affects the metabolism of Irinotecan] |
CTD |
PMID:24727322 |
|
NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
decreases response to substance |
ISO |
ABCB6 protein results in decreased susceptibility to Irinotecan |
CTD |
PMID:25202056 |
|
NCBI chr 9:84,117,222...84,125,939
Ensembl chr 9:76,668,554...76,676,924
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases response to substance multiple interactions decreases expression |
ISO |
ABCC1 protein results in decreased susceptibility to Irinotecan [selenomethylselenocysteine co-treated with Irinotecan] results in decreased expression of ABCC1 Irinotecan analog results in decreased expression of ABCC1 mRNA |
CTD |
PMID:15897249 PMID:16815871 PMID:18927307 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects response to substance decreases response to substance |
ISO |
ABCC2 gene polymorphism affects the susceptibility to Irinotecan; ABCC2 gene polymorphism affects the susceptibility to Irinotecan metabolite ABCC2 protein results in decreased susceptibility to Irinotecan ABCC2 gene mutant form results in decreased susceptibility to Irinotecan |
CTD |
PMID:16815871 PMID:18981587 PMID:32387182 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
affects export |
ISO |
ABCC4 protein affects the export of Irinotecan |
CTD |
PMID:15827327 |
|
NCBI chr15:101,948,387...102,182,912
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions affects export decreases response to substance affects metabolic processing affects response to substance increases response to substance increases transport |
ISO |
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCG2 protein affects the metabolism of Irinotecan]; Everolimus inhibits the reaction [ABCG2 protein affects the metabolism of Irinotecan] ABCG2 protein affects the export of Irinotecan ABCG2 protein results in decreased susceptibility to Irinotecan; ABCG2 results in decreased susceptibility to Irinotecan ABCG2 gene polymorphism affects the susceptibility to and affects the metabolism of Irinotecan; Porphyrins inhibits the reaction [ABCG2 protein results in decreased susceptibility to Irinotecan]; Reserpine inhibits the reaction [ABCG2 protein results in increased transport of Irinotecan] ABCG2 affects the susceptibility to Irinotecan ABCG2 mRNA results in increased susceptibility to Irinotecan; ABCG2 protein results in increased susceptibility to Irinotecan ABCG2 gene mutant form results in increased susceptibility to Irinotecan |
CTD |
PMID:10606239 PMID:12869632 PMID:15239142 PMID:15655543 PMID:15695404 PMID:15801936 PMID:16542215 PMID:16954373 PMID:24727322 PMID:32387182 PMID:34717915 More...
|
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abhd13 |
abhydrolase domain containing 13 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ABHD13 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr16:79,501,879...79,516,712
Ensembl chr16:79,501,727...79,516,748
|
|
G |
Abi2 |
abl-interactor 2 |
decreases expression |
ISO |
Irinotecan results in decreased expression of ABI2 mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 9:69,321,072...69,490,630
Ensembl chr 9:61,827,139...61,905,699
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ACACA mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
increases response to substance |
ISO |
ACAT1 protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 8:62,876,003...62,905,080
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
EXP |
Irinotecan results in decreased activity of ACHE protein |
CTD |
PMID:11740913 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
ISO |
Irinotecan results in increased expression of ACTA2 protein Silymarin affects the reaction [Irinotecan results in increased expression of ACTA2 protein] |
CTD |
PMID:28454924 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ada |
adenosine deaminase |
affects expression |
EXP |
Irinotecan affects the expression of ADA mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
increases expression |
ISO |
Irinotecan analog results in increased expression of ADAM19 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
increases expression |
EXP |
Irinotecan results in increased expression of ADAMTS1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr11:38,418,565...38,427,384
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Add3 |
adducin 3 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of ADD3 mRNA; Irinotecan results in decreased expression of ADD3 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
affects expression |
EXP |
Irinotecan affects the expression of ADH1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adi1 |
acireductone dioxygenase 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ADI1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 6:45,306,885...45,313,847
Ensembl chr 6:45,306,841...45,313,842
|
|
G |
Adk |
adenosine kinase |
affects expression |
EXP |
Irinotecan affects the expression of ADK mRNA |
CTD |
PMID:20097248 |
|
NCBI chr15:2,912,543...3,295,745
Ensembl chr15:2,863,244...3,246,510
|
|
G |
Agpat4 |
1-acylglycerol-3-phosphate O-acyltransferase 4 |
affects expression |
EXP |
Irinotecan affects the expression of AGPAT4 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 1:48,525,131...48,633,798
Ensembl chr 1:48,527,323...48,633,345
|
|
G |
Agt |
angiotensinogen |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of AGT mRNA |
CTD |
PMID:18927307 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahcyl1 |
adenosylhomocysteinase-like 1 |
affects expression |
EXP |
Irinotecan affects the expression of AHCYL1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 2:197,982,335...198,016,770
Ensembl chr 2:195,294,153...195,345,815
|
|
G |
Ak2 |
adenylate kinase 2 |
increases response to substance |
ISO |
AK2 protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 5:146,609,469...146,649,008
Ensembl chr 5:141,346,063...141,364,632
|
|
G |
Akap10 |
A-kinase anchoring protein 10 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of AKAP10 mRNA; Irinotecan results in decreased expression of AKAP10 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr10:46,545,371...46,608,730
Ensembl chr10:46,551,532...46,608,769
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of ALAS2 mRNA; Irinotecan results in increased expression of ALAS2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr X:22,890,650...22,914,046
Ensembl chr X:19,463,171...19,486,519
|
|
G |
Alb |
albumin |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ALB mRNA |
CTD |
PMID:18927307 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
decreases expression |
EXP |
Irinotecan results in decreased expression of ALDH18A1 mRNA |
CTD |
PMID:30012503 |
|
NCBI chr 1:249,325,082...249,357,383
Ensembl chr 1:239,375,669...239,407,890
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of ALDH1A1 mRNA; Irinotecan results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
increases expression |
ISO |
Irinotecan analog results in increased expression of AMIGO2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:130,270,639...130,273,735
Ensembl chr 7:128,390,412...128,394,695
|
|
G |
Amy1 |
amylase alpha 1 |
affects expression |
EXP |
Irinotecan affects the expression of AMY1A mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 2:204,071,101...204,085,910
Ensembl chr 2:201,382,675...201,397,816
|
|
G |
Angptl2 |
angiopoietin-like 2 |
multiple interactions |
ISO |
ANGPTL2 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] |
CTD |
PMID:17327601 |
|
NCBI chr 3:36,914,876...36,944,715
Ensembl chr 3:16,517,420...16,548,178
|
|
G |
Ankh |
ANKH inorganic pyrophosphate transport regulator |
affects expression |
EXP |
Irinotecan affects the expression of ANKH mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 2:79,883,350...80,011,222
Ensembl chr 2:78,153,026...78,280,187
|
|
G |
Ankrd17 |
ankyrin repeat domain 17 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ANKRD17 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr14:18,007,342...18,145,980
Ensembl chr14:17,721,932...17,862,617
|
|
G |
Ankrd28 |
ankyrin repeat domain 28 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ANKRD28 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr16:6,918,487...7,050,244
Ensembl chr16:6,914,336...7,050,249
|
|
G |
Anxa13 |
annexin A13 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ANXA13 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:89,884,356...89,936,907
Ensembl chr 7:89,884,356...89,936,907
|
|
G |
Anxa2 |
annexin A2 |
increases expression multiple interactions |
ISO |
Irinotecan results in increased expression of ANXA2 mRNA [PHY 906 co-treated with Irinotecan] affects the expression of ANXA2 mRNA |
CTD |
PMID:15152939 PMID:32812032 |
|
NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa6 |
annexin A6 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of ANXA6 mRNA; Irinotecan results in increased expression of ANXA6 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr10:39,602,106...39,657,183
Ensembl chr10:39,097,109...39,156,433
|
|
G |
Ap2b1 |
adaptor related protein complex 2 subunit beta 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of AP2B1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:68,099,397...68,205,023
Ensembl chr10:68,099,547...68,205,013
|
|
G |
Ap2s1 |
adaptor related protein complex 2 subunit sigma 1 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in decreased expression of AP2S1 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr 1:77,417,496...77,428,903
Ensembl chr 1:77,417,477...77,428,905
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of APC mRNA; Irinotecan results in decreased expression of APC mRNA |
CTD |
PMID:15956246 |
|
NCBI chr18:26,138,382...26,196,021
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Araf |
A-Raf proto-oncogene, serine/threonine kinase |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of ARAF mRNA; Irinotecan results in increased expression of ARAF mRNA |
CTD |
PMID:15956246 |
|
NCBI chr X:3,780,932...3,845,919
Ensembl chr X:1,227,392...1,239,073
|
|
G |
Areg |
amphiregulin |
multiple interactions increases expression |
ISO |
Gefitinib inhibits the reaction [Irinotecan metabolite results in increased expression of AREG mRNA]; Gefitinib inhibits the reaction [Irinotecan results in increased expression of AREG mRNA] Irinotecan metabolite results in increased expression of AREG mRNA; Irinotecan results in increased expression of AREG mRNA |
CTD |
PMID:15723263 |
|
NCBI chr14:17,256,384...17,265,641
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arf1 |
ARF GTPase 1 |
multiple interactions decreases expression |
ISO |
ARF1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] Irinotecan analog results in decreased expression of ARF1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434
|
|
G |
Arg2 |
arginase 2 |
affects expression |
EXP |
Irinotecan affects the expression of ARG2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 6:103,669,001...103,694,375
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
decreases expression increases expression |
ISO |
Irinotecan metabolite results in decreased expression of ARHGAP5 mRNA; Irinotecan results in decreased expression of ARHGAP5 mRNA Irinotecan metabolite results in increased expression of ARHGAP5 mRNA; Irinotecan results in increased expression of ARHGAP5 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 6:75,711,199...75,774,636
Ensembl chr 6:69,976,214...70,037,660
|
|
G |
Arhgef12 |
Rho guanine nucleotide exchange factor 12 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ARHGEF12 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366
|
|
G |
Arhgef39 |
Rho guanine nucleotide exchange factor 39 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ARHGEF39 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:62,548,300...62,551,870
Ensembl chr 5:57,752,509...57,756,109
|
|
G |
Arid2 |
AT-rich interaction domain 2 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ARID2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:129,326,371...129,443,813
Ensembl chr 7:127,447,278...127,563,512
|
|
G |
Arid4a |
AT-rich interaction domain 4A |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of ARID4A mRNA; Irinotecan results in decreased expression of ARID4A mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 6:95,258,429...95,335,987
Ensembl chr 6:89,522,442...89,593,510
|
|
G |
Arl4c |
ARF like GTPase 4C |
increases expression |
ISO |
Irinotecan analog results in increased expression of ARL4C mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 9:96,748,075...96,751,510
Ensembl chr 9:89,298,005...89,304,513
|
|
G |
Armc8 |
armadillo repeat containing 8 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ARMC8 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 8:108,916,274...109,010,877
Ensembl chr 8:100,036,946...100,131,520
|
|
G |
Arsb |
arylsulfatase B |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ARSB mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:26,736,395...26,895,682
Ensembl chr 2:25,002,346...25,162,671
|
|
G |
As3mt |
arsenite methyltransferase |
affects expression |
EXP |
Irinotecan affects the expression of AS3MT mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872
|
|
G |
Asb2 |
ankyrin repeat and SOCS box-containing 2 |
affects expression |
EXP |
Irinotecan affects the expression of ASB2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 6:128,239,550...128,275,833
Ensembl chr 6:122,474,756...122,510,854
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in decreased expression of ASS1 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of ATF3 mRNA; Irinotecan results in increased expression of ATF3 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr13:105,274,103...105,331,653
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atg10 |
autophagy related 10 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of ATG10 mRNA; Irinotecan results in decreased expression of ATG10 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 2:22,109,304...22,398,313
Ensembl chr 2:22,108,426...22,398,233
|
|
G |
Atl2 |
atlastin GTPase 2 |
increases expression |
ISO |
Irinotecan analog results in increased expression of ATL2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 6:20,891,220...20,932,644
Ensembl chr 6:15,139,044...15,180,421
|
|
G |
Atm |
ATM serine/threonine kinase |
increases phosphorylation |
ISO |
Irinotecan results in increased phosphorylation of ATM protein |
CTD |
PMID:22898888 |
|
NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
affects expression |
EXP |
Irinotecan affects the expression of ATP2B1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 7:35,622,267...35,731,904
Ensembl chr 7:33,735,871...33,843,295
|
|
G |
Atp2b4 |
ATPase plasma membrane Ca2+ transporting 4 |
decreases response to substance |
ISO |
ATP2B4 protein results in decreased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr13:47,708,157...47,807,389
Ensembl chr13:45,156,146...45,255,246
|
|
G |
Atp5po |
ATP synthase peripheral stalk subunit OSCP |
multiple interactions |
ISO |
ATP5PO mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] |
CTD |
PMID:17327601 |
|
NCBI chr11:44,651,171...44,657,483
Ensembl chr11:31,165,217...31,171,592
|
|
G |
Atp6v0b |
ATPase H+ transporting V0 subunit B |
increases response to substance |
ISO |
ATP6V0B protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 5:136,708,823...136,710,339
Ensembl chr 5:131,423,387...131,426,401
|
|
G |
Atp7a |
ATPase copper transporting alpha |
decreases response to substance increases export |
ISO |
ATP7A protein results in decreased susceptibility to Irinotecan ATP7A protein results in increased export of Irinotecan |
CTD |
PMID:17510416 |
|
NCBI chr X:75,159,635...75,267,094
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
affects expression |
EXP |
Irinotecan affects the expression of ATP8B1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr18:60,286,605...60,427,862
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Atrx |
ATRX, chromatin remodeler |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ATRX mRNA |
CTD |
PMID:18927307 |
|
NCBI chr X:74,916,548...75,062,880
Ensembl chr X:70,850,981...70,997,330
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of AURKB mRNA; Irinotecan results in decreased expression of AURKB mRNA |
CTD |
PMID:15956246 |
|
NCBI chr10:54,243,116...54,249,675
Ensembl chr10:53,745,142...53,750,837
|
|
G |
B2m |
beta-2 microglobulin |
increases expression |
EXP |
Irinotecan results in increased expression of B2M mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
increases expression |
ISO |
Irinotecan analog results in increased expression of BAMBI mRNA |
CTD |
PMID:18927307 |
|
NCBI chr17:58,816,438...58,821,003
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan co-treated with Vorinostat] results in increased expression of BAX protein |
CTD |
PMID:15754201 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions affects response to substance |
ISO |
[Fluorouracil co-treated with Irinotecan co-treated with Vorinostat] results in decreased expression of BCL2 protein; [Fluorouracil co-treated with Irinotecan] results in decreased expression of BCL2 mRNA; [Fluorouracil co-treated with Irinotecan] results in decreased expression of BCL2 protein BCL2 protein affects the susceptibility to Irinotecan |
CTD |
PMID:15754201 PMID:16391804 PMID:18949393 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
Irinotecan results in decreased expression of BCL2L1 mRNA Irinotecan promotes the reaction [AS602868 results in decreased expression of BCL2L1 mRNA] |
CTD |
PMID:16432164 PMID:18182997 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bcl7a |
BAF chromatin remodeling complex subunit BCL7A |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of BCL7A mRNA; Irinotecan results in increased expression of BCL7A mRNA |
CTD |
PMID:15956246 |
|
NCBI chr12:38,872,851...38,904,770
Ensembl chr12:33,223,931...33,243,886
|
|
G |
Bcl9 |
BCL9, transcription coactivator |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of BCL9 mRNA; Irinotecan results in increased expression of BCL9 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 2:187,449,425...187,475,241
Ensembl chr 2:184,760,618...184,786,435
|
|
G |
Bcr |
BCR activator of RhoGEF and GTPase |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of BCR mRNA |
CTD |
PMID:18927307 |
|
NCBI chr20:13,468,732...13,596,333
Ensembl chr20:13,471,668...13,597,016
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions decreases expression |
ISO |
[Fluorouracil co-treated with Irinotecan co-treated with Vorinostat] results in increased cleavage of BID protein Irinotecan results in decreased expression of BID protein |
CTD |
PMID:15754201 |
|
NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
affects expression |
EXP |
Irinotecan affects the expression of BIRC3 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression multiple interactions |
ISO |
Irinotecan metabolite results in decreased expression of BIRC5 mRNA; Irinotecan results in decreased expression of BIRC5 mRNA [Irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; Irinotecan promotes the reaction [AS602868 results in decreased expression of BIRC5 mRNA] |
CTD |
PMID:15956246 PMID:16373703 PMID:18182997 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmp8a |
bone morphogenetic protein 8a |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of BMP8A mRNA; Irinotecan results in increased expression of BMP8A mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 5:135,589,839...135,617,785
Ensembl chr 5:135,591,716...135,617,785
|
|
G |
Bod1l1 |
biorientation of chromosomes in cell division 1-like 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of BOD1L1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr14:73,320,880...73,375,662
Ensembl chr14:69,108,491...69,162,490
|
|
G |
Boll |
boule homolog, RNA binding protein |
multiple interactions |
ISO |
BOLL mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] |
CTD |
PMID:17327601 |
|
NCBI chr 9:64,225,411...64,354,394
Ensembl chr 9:56,733,584...56,859,916
|
|
G |
Btbd3 |
BTB domain containing 3 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of BTBD3 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 3:146,044,053...146,074,189
Ensembl chr 3:125,591,490...125,619,038
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
decreases expression affects expression |
ISO EXP |
Irinotecan metabolite results in decreased expression of BUB1 mRNA; Irinotecan results in decreased expression of BUB1 mRNA Irinotecan affects the expression of BUB1 mRNA |
CTD |
PMID:15956246 PMID:20097248 |
|
NCBI chr 3:135,473,525...135,504,921
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
C19h16orf87 |
similar to human chromosome 16 open reading frame 87 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of C16ORF87 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr19:21,626,390...21,653,869
Ensembl chr19:21,626,914...21,654,255
|
|
G |
C1qc |
complement C1q C chain |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of C1QC mRNA |
CTD |
PMID:32812032 |
|
NCBI chr 5:154,410,845...154,414,208
Ensembl chr 5:149,127,415...149,131,017
|
|
G |
C2 |
complement C2 |
affects expression |
EXP |
Irinotecan affects the expression of C2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr20:3,944,722...3,975,006
Ensembl chr20:3,951,474...3,976,505
|
|
G |
C3ar1 |
complement C3a receptor 1 |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of C3AR1 mRNA |
CTD |
PMID:32812032 |
|
NCBI chr 4:157,747,419...157,756,609
Ensembl chr 4:156,075,389...156,084,701
|
|
G |
C7 |
complement C7 |
increases expression |
EXP |
Irinotecan results in increased expression of C7 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 2:55,815,687...55,892,605
Ensembl chr 2:54,088,116...54,158,535
|
|
G |
Cabin1 |
calcineurin binding protein 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CABIN1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr20:12,892,750...13,014,801
Ensembl chr20:12,893,358...13,015,357
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CACNA1I mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:113,716,266...113,827,670
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Casp1 |
caspase 1 |
increases cleavage multiple interactions affects expression |
ISO EXP |
Irinotecan results in increased cleavage of CASP1 protein [Irinotecan co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein Irinotecan affects the expression of CASP1 mRNA [Irinotecan co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; EVP 4593 inhibits the reaction [Irinotecan results in increased cleavage of CASP1 protein]; pyrazolanthrone inhibits the reaction [Irinotecan results in increased cleavage of CASP1 protein] |
CTD |
PMID:20097248 PMID:26431797 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression |
ISO |
[Irinotecan co-treated with alvocidib] results in increased activity of CASP3 protein; [Irinotecan co-treated with rucaparib] results in increased expression of CASP3 protein; Irinotecan promotes the reaction [AS602868 results in increased cleavage of and results in increased activity of CASP3 protein]; RNF34 protein inhibits the reaction [Irinotecan results in increased activity of CASP3 protein]; Ursodeoxycholic Acid promotes the reaction [Irinotecan results in increased activity of CASP3 protein] Irinotecan results in increased expression of CASP3 protein |
CTD |
PMID:11751522 PMID:16080519 PMID:16432164 PMID:18182997 PMID:22898888 PMID:30612311 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of CASP4 mRNA; Irinotecan results in decreased expression of CASP4 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
Irinotecan promotes the reaction [AS602868 results in increased cleavage of and results in increased activity of CASP8 protein]; Irinotecan results in increased cleavage of and results in increased activity of CASP8 protein; Ursodeoxycholic Acid promotes the reaction [Irinotecan results in increased activity of CASP8 protein] |
CTD |
PMID:16432164 PMID:18182997 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Irinotecan results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Irinotecan results in increased activity of CASP9 protein]; Irinotecan promotes the reaction [AS602868 results in increased cleavage of and results in increased activity of CASP9 protein]; Irinotecan results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:18182997 PMID:22898888 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cblc |
Cbl proto-oncogene C |
affects expression |
EXP |
Irinotecan affects the expression of CBLC mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 1:88,567,930...88,584,709
Ensembl chr 1:79,439,977...79,456,755
|
|
G |
Cck |
cholecystokinin |
affects expression |
EXP |
Irinotecan affects the expression of CCK mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 8:130,031,012...130,037,702
Ensembl chr 8:121,153,500...121,160,084
|
|
G |
Ccn1 |
cellular communication network factor 1 |
decreases response to substance |
ISO |
CCN1 protein results in decreased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
ISO |
Irinotecan results in increased expression of CCN2 mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of CCNA2 mRNA; Irinotecan results in decreased expression of CCNA2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
EXP |
Irinotecan results in decreased expression of CCNB1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb1ip1 |
cyclin B1 interacting protein 1 |
increases response to substance |
ISO |
CCNB1IP1 protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr15:26,488,462...26,504,167
Ensembl chr15:24,014,908...24,028,475
|
|
G |
Ccnb2 |
cyclin B2 |
increases response to substance decreases expression |
ISO EXP |
CCNB2 protein results in increased susceptibility to Irinotecan Irinotecan metabolite results in decreased expression of CCNB2 mRNA; Irinotecan results in decreased expression of CCNB2 mRNA |
CTD |
PMID:15956246 PMID:16734730 PMID:20097248 |
|
NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccnf |
cyclin F |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of CCNF mRNA; Irinotecan results in decreased expression of CCNF mRNA |
CTD |
PMID:15956246 |
|
NCBI chr10:13,757,884...13,783,669
Ensembl chr10:13,253,380...13,279,101
|
|
G |
Ccng2 |
cyclin G2 |
increases expression |
ISO |
Irinotecan analog results in increased expression of CCNG2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr14:15,088,694...15,097,190
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of CCR1 mRNA; Irinotecan results in increased expression of CCR1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 8:132,433,711...132,439,266
|
|
G |
Ccr6 |
C-C motif chemokine receptor 6 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of CCR6 mRNA; Irinotecan results in decreased expression of CCR6 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 1:55,022,037...55,055,857
Ensembl chr 1:52,474,168...52,498,603
|
|
G |
Cct6a |
chaperonin containing TCP1 subunit 6A |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CCT6A mRNA |
CTD |
PMID:18927307 |
|
NCBI chr12:32,508,842...32,519,072
Ensembl chr12:26,872,574...26,883,337
|
|
G |
Cd163 |
CD163 molecule |
increases expression |
EXP |
Irinotecan results in increased expression of CD163 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:158,770,751...158,804,146
Ensembl chr 4:157,085,093...157,117,878
|
|
G |
Cd36 |
CD36 molecule |
affects expression |
EXP |
Irinotecan affects the expression of CD36 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:18,209,088...18,302,142
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd47 |
Cd47 molecule |
increases expression |
ISO |
Irinotecan analog results in increased expression of CD47 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr11:64,374,816...64,438,763
Ensembl chr11:50,906,177...50,969,425
|
|
G |
Cd70 |
Cd70 molecule |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of CD70 mRNA; Irinotecan results in increased expression of CD70 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 9:2,093,540...2,096,692
Ensembl chr 9:2,006,563...2,009,715
|
|
G |
Cd80 |
Cd80 molecule |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of CD80 mRNA; Irinotecan results in increased expression of CD80 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr11:75,760,073...75,798,978
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cdc20 |
cell division cycle 20 |
affects expression increases response to substance |
EXP ISO |
Irinotecan affects the expression of CDC20 mRNA CDC20 protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 PMID:20097248 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc25b |
cell division cycle 25B |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of CDC25B mRNA; Irinotecan results in decreased expression of CDC25B mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 3:138,860,148...138,870,287
Ensembl chr 3:118,407,128...118,417,272
|
|
G |
Cdc42bpa |
CDC42 binding protein kinase alpha |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CDC42BPA mRNA |
CTD |
PMID:18927307 |
|
NCBI chr13:94,215,359...94,435,681
Ensembl chr13:91,684,007...91,903,732
|
|
G |
Cdca3 |
cell division cycle associated 3 |
decreases expression |
EXP |
Irinotecan results in decreased expression of CDCA3 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:159,321,203...159,325,072
Ensembl chr 4:157,634,928...157,638,799
|
|
G |
Cdh1 |
cadherin 1 |
affects response to substance |
ISO |
CDH1 protein affects the susceptibility to Irinotecan |
CTD |
PMID:34075792 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh4 |
cadherin 4 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CDH4 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 3:186,902,763...187,381,020
Ensembl chr 3:166,525,099...167,003,371
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
EXP ISO |
Irinotecan results in decreased expression of CDK1 mRNA Irinotecan metabolite results in decreased expression of CDK1 mRNA; Irinotecan results in decreased expression of CDK1 mRNA |
CTD |
PMID:15956246 PMID:20097248 |
|
NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk13 |
cyclin-dependent kinase 13 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of CDK13 mRNA; Irinotecan results in decreased expression of CDK13 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr17:51,945,975...52,040,218
Ensembl chr17:47,251,163...47,341,721
|
|
G |
Cdk5r2 |
cyclin-dependent kinase 5 regulatory subunit 2 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of CDK5R2 mRNA; Irinotecan results in increased expression of CDK5R2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 9:76,416,251...76,417,719
Ensembl chr 9:76,416,062...76,418,344
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
affects expression |
ISO |
Irinotecan analog affects the expression of CDK6 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression affects expression multiple interactions |
ISO |
Irinotecan results in increased expression of CDKN1A mRNA; Irinotecan results in increased expression of CDKN1A protein Irinotecan affects the expression of CDKN1A protein [Fluorouracil co-treated with Irinotecan co-treated with Vorinostat] results in increased expression of CDKN1A protein |
CTD |
PMID:15132777 PMID:15754201 PMID:22510560 PMID:22898888 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
affects expression decreases expression increases response to substance |
ISO |
Irinotecan affects the expression of CDKN2A protein Irinotecan results in decreased expression of CDKN2A mRNA CDKN2A results in increased susceptibility to Irinotecan |
CTD |
PMID:16432164 PMID:22898888 |
|
NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
ISO EXP |
Irinotecan metabolite results in decreased expression of CDKN3 mRNA; Irinotecan results in decreased expression of CDKN3 mRNA |
CTD |
PMID:15956246 PMID:20097248 |
|
NCBI chr15:22,502,299...22,513,725
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cdon |
cell adhesion associated, oncogene regulated |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CDON mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 8:42,032,921...42,119,451
Ensembl chr 8:33,806,183...33,859,033
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
EXP |
Irinotecan results in increased expression of CEBPD mRNA |
CTD |
PMID:20097248 |
|
NCBI chr11:98,268,856...98,269,994
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Cel |
carboxyl ester lipase |
increases response to substance |
ISO |
CEL protein results in increased susceptibility to Irinotecan |
CTD |
PMID:9766666 |
|
NCBI chr 3:32,281,518...32,289,019
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Cela3b |
chymotrypsin like elastase 3B |
affects expression |
EXP |
Irinotecan affects the expression of CELA3B mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 5:149,628,773...149,636,937
Ensembl chr 5:149,628,773...149,636,937
|
|
G |
Cenpe |
centromere protein E |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CENPE mRNA; Irinotecan metabolite results in decreased expression of CENPE mRNA; Irinotecan results in decreased expression of CENPE mRNA |
CTD |
PMID:15956246 PMID:18927307 |
|
NCBI chr 2:226,310,970...226,369,636
Ensembl chr 2:223,636,998...223,695,669
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of CENPF mRNA; Irinotecan results in decreased expression of CENPF mRNA |
CTD |
PMID:15956246 |
|
NCBI chr13:103,715,344...103,760,931
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cep192 |
centrosomal protein 192 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CEP192 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr18:63,643,816...63,728,264
Ensembl chr18:61,332,158...61,458,379
|
|
G |
Cep290 |
centrosomal protein 290 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CEP290 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:37,196,765...37,285,955
Ensembl chr 7:35,310,199...35,399,392
|
|
G |
Cep295 |
centrosomal protein 295 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CEP295 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 8:20,437,967...20,475,968
Ensembl chr 8:12,156,554...12,194,552
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis increases response to substance |
ISO |
CES1 protein results in increased hydrolysis of Irinotecan CES1 mRNA results in increased susceptibility to Irinotecan |
CTD |
PMID:15100172 PMID:15239142 |
|
NCBI chr19:30,046,494...30,085,039
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
increases expression increases hydrolysis affects response to substance increases metabolic processing increases chemical synthesis increases response to substance multiple interactions |
ISO |
Irinotecan results in increased expression of CES2 mRNA CES2 protein results in increased hydrolysis of Irinotecan CES2 protein affects the susceptibility to Irinotecan CES2 protein results in increased metabolism of Irinotecan CES2 protein results in increased chemical synthesis of Irinotecan CES2 protein results in increased susceptibility to Irinotecan CES2 mRNA results in increased chemical synthesis of and results in increased abundance of Irinotecan; CES2 mRNA results in increased metabolism of and results in increased activity of Irinotecan; CES2 protein affects the metabolism of and results in increased activity of Irinotecan; CES2 protein results in increased hydrolysis of and results in increased activity of Irinotecan; CES2 protein results in increased metabolism of and results in increased activity of Irinotecan |
CTD |
PMID:10728672 PMID:11716702 PMID:12171891 PMID:12171903 PMID:14581373 PMID:15100172 PMID:15475733 PMID:15592324 PMID:15655543 PMID:16203781 PMID:16963839 More...
|
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Ces3a |
carboxylesterase 3a |
increases hydrolysis |
ISO |
CES3 protein results in increased hydrolysis of Irinotecan |
CTD |
PMID:15100172 |
|
NCBI chr19:32,992,386...33,000,562
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression multiple interactions affects response to substance |
ISO |
Irinotecan results in decreased expression of CFLAR protein CFLAR protein alternative form inhibits the reaction [Irinotecan results in increased activity of TNFSF10 protein] CFLAR protein affects the susceptibility to Irinotecan |
CTD |
PMID:16373718 |
|
NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects expression |
EXP |
Irinotecan affects the expression of CFTR mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chd1 |
chromodomain helicase DNA binding protein 1 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of CHD1 mRNA; Irinotecan results in decreased expression of CHD1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 1:65,334,905...65,402,270
Ensembl chr 1:56,664,054...56,728,125
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Irinotecan results in increased phosphorylation of CHEK1 protein Irinotecan results in increased phosphorylation of and results in increased activity of CHEK1 protein; SAR 020106 inhibits the reaction [Irinotecan results in increased phosphorylation of CHEK1 protein] |
CTD |
PMID:22111927 PMID:22510560 PMID:22898888 |
|
NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases phosphorylation |
ISO |
Irinotecan results in increased phosphorylation of CHEK2 protein |
CTD |
PMID:22898888 |
|
NCBI chr12:51,448,838...51,481,159
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
decreases expression |
EXP |
Irinotecan results in decreased expression of CKS2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr17:13,722,360...13,727,519
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions decreases expression |
ISO |
GSK484 inhibits the reaction [Irinotecan results in decreased expression of CLDN1 protein]; phenethyl isothiocyanate inhibits the reaction [Irinotecan results in decreased expression of CLDN1 protein] |
CTD |
PMID:38341106 |
|
NCBI chr11:87,926,376...87,941,533
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn2 |
claudin 2 |
affects expression |
EXP |
Irinotecan affects the expression of CLDN2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr X:108,248,383...108,258,847
Ensembl chr X:103,459,780...103,474,838
|
|
G |
Clec10a |
C-type lectin domain containing 10A |
increases expression |
EXP |
Irinotecan results in increased expression of CLEC10A mRNA |
CTD |
PMID:20097248 |
|
NCBI chr10:55,374,914...55,379,110
Ensembl chr10:54,876,260...54,880,435
|
|
G |
Clgn |
calmegin |
increases expression |
ISO |
Irinotecan analog results in increased expression of CLGN mRNA |
CTD |
PMID:18927307 |
|
NCBI chr19:41,601,568...41,633,207
Ensembl chr19:24,696,875...24,728,758
|
|
G |
Clps |
colipase |
affects expression |
EXP |
Irinotecan affects the expression of CLPS mRNA |
CTD |
PMID:20097248 |
|
NCBI chr20:6,622,234...6,624,414
Ensembl chr20:6,620,529...6,622,689
|
|
G |
Cltc |
clathrin heavy chain |
decreases expression multiple interactions |
ISO |
Irinotecan analog results in decreased expression of CLTC mRNA CLTC protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] |
CTD |
PMID:18927307 |
|
NCBI chr10:72,014,984...72,073,308
Ensembl chr10:71,517,663...71,573,737
|
|
G |
Cnnm2 |
cyclin and CBS domain divalent metal cation transport mediator 2 |
increases expression |
ISO |
Irinotecan analog results in increased expression of CNNM2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:245,643,682...245,769,542
Ensembl chr 1:245,643,768...245,763,286
|
|
G |
Col13a1 |
collagen type XIII alpha 1 chain |
increases expression |
ISO |
Irinotecan analog results in increased expression of COL13A1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr20:29,783,965...29,924,116
Ensembl chr20:29,783,965...29,924,032
|
|
G |
Col4a4 |
collagen type IV alpha 4 chain |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of COL4A4 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 9:91,281,324...91,323,577
Ensembl chr 9:83,755,515...83,875,876
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of COL6A1 mRNA; Irinotecan results in increased expression of COL6A1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr20:11,905,690...11,924,111
Ensembl chr20:11,905,957...11,924,597
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
decreases response to substance |
ISO |
COL7A1 protein results in decreased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 8:118,483,364...118,515,736
Ensembl chr 8:109,604,861...109,637,252
|
|
G |
Commd6 |
COMM domain containing 6 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of COMMD6 mRNA; Irinotecan results in increased expression of COMMD6 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr15:78,467,333...78,474,382
Ensembl chr15:78,467,804...78,474,382
|
|
G |
Copa |
COPI coat complex subunit alpha |
increases expression |
ISO |
Irinotecan analog results in increased expression of COPA mRNA |
CTD |
PMID:18927307 |
|
NCBI chr13:87,078,853...87,119,256
Ensembl chr13:84,545,943...84,586,874
|
|
G |
Coq9 |
coenzyme Q9 |
decreases expression |
ISO |
Irinotecan results in decreased expression of COQ9 mRNA |
CTD |
PMID:20185912 |
|
NCBI chr19:10,172,943...10,185,960
Ensembl chr19:10,166,951...10,179,949
|
|
G |
Cpe |
carboxypeptidase E |
increases expression |
ISO |
Irinotecan analog results in increased expression of CPE mRNA |
CTD |
PMID:18927307 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Crebbp |
CREB binding protein |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CREBBP mRNA; Irinotecan metabolite results in decreased expression of CREBBP mRNA; Irinotecan results in decreased expression of CREBBP mRNA |
CTD |
PMID:15956246 PMID:18927307 |
|
NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crim1 |
cysteine rich transmembrane BMP regulator 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CRIM1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 6:16,695,864...16,870,264
Ensembl chr 6:16,697,829...16,870,259
|
|
G |
Ctbp2 |
C-terminal binding protein 2 |
decreases expression multiple interactions |
ISO |
Irinotecan analog results in decreased expression of CTBP2 mRNA [Fluorouracil co-treated with Irinotecan] results in decreased expression of CTBP2 mRNA; CTBP2 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] |
CTD |
PMID:16391804 PMID:18927307 |
|
NCBI chr 1:197,208,536...197,348,802
Ensembl chr 1:187,782,682...187,920,222
|
|
G |
Cth |
cystathionine gamma-lyase |
increases expression |
ISO |
Irinotecan analog results in increased expression of CTH mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:249,634,731...249,661,066
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Cul4a |
cullin 4A |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CUL4A mRNA |
CTD |
PMID:18927307 |
|
NCBI chr16:83,086,688...83,124,503
Ensembl chr16:76,384,546...76,422,330
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
affects expression |
EXP |
Irinotecan affects the expression of CXCL11 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr14:15,973,728...15,976,503
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of CXCL12 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression multiple interactions |
ISO |
Irinotecan results in increased expression of CXCL1 protein 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [carvacrol inhibits the reaction [Irinotecan results in increased expression of CXCL1 protein]]; carvacrol inhibits the reaction [Irinotecan results in increased expression of CXCL1 protein] |
CTD |
PMID:27838229 |
|
NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
affects expression |
EXP |
Irinotecan affects the expression of CYP27A1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity increases oxidation increases response to substance affects metabolic processing |
ISO |
Irinotecan metabolite results in decreased activity of CYP3A4 protein; Irinotecan results in decreased activity of CYP3A4 protein CYP3A4 protein results in increased oxidation of Irinotecan CYP3A4 mRNA results in increased susceptibility to Irinotecan CYP3A4 protein affects the metabolism of Irinotecan |
CTD |
PMID:11901092 PMID:15100172 PMID:15239142 PMID:15523087 PMID:15655543 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
[selenomethylselenocysteine co-treated with Irinotecan] results in increased expression of CYP3A5 |
CTD |
PMID:15897249 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
affects expression |
EXP |
Irinotecan affects the expression of CYP4B1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 5:134,375,807...134,413,635
Ensembl chr 5:129,139,038...129,156,348
|
|
G |
Cyp4f1 |
cytochrome P450, family 4, subfamily f, polypeptide 1 |
affects expression |
EXP |
Irinotecan affects the expression of CYP4F1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 7:12,661,357...12,672,952
Ensembl chr 7:12,010,852...12,022,046
|
|
G |
Daglb |
diacylglycerol lipase, beta |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DAGLB mRNA |
CTD |
PMID:18927307 |
|
NCBI chr12:16,173,345...16,215,777
Ensembl chr12:11,059,732...11,102,154
|
|
G |
Dbf4 |
DBF4-CDC7 kinase regulatory subunit |
increases response to substance |
ISO |
DBF4 protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066
|
|
G |
Dcaf8 |
DDB1 and CUL4 associated factor 8 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DCAF8 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr13:87,141,940...87,199,859
Ensembl chr13:84,610,248...84,669,726
|
|
G |
Dclre1a |
DNA cross-link repair 1A |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of DCLRE1A mRNA; Irinotecan results in decreased expression of DCLRE1A mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 1:265,575,087...265,594,987
Ensembl chr 1:255,569,919...255,589,678
|
|
G |
Dctn2 |
dynactin subunit 2 |
increases expression |
ISO |
Irinotecan analog results in increased expression of DCTN2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:63,092,061...63,107,560
Ensembl chr 7:63,092,057...63,108,543
|
|
G |
Ddb2 |
damage specific DNA binding protein 2 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of DDB2 mRNA; Irinotecan results in increased expression of DDB2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 3:97,640,923...97,667,617
Ensembl chr 3:77,185,109...77,207,631
|
|
G |
Ddhd1 |
DDHD domain containing 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DDHD1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr15:21,304,053...21,370,608
Ensembl chr15:18,824,394...18,890,952
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
EXP |
Irinotecan results in increased expression of DDIT3 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
EXP |
Irinotecan results in increased expression of DDIT4 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr20:28,434,938...28,437,037
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddx17 |
DEAD-box helicase 17 |
decreases expression |
ISO |
Irinotecan results in decreased expression of DDX17 mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 7:112,971,522...112,989,747
Ensembl chr 7:111,089,445...111,109,193
|
|
G |
Ddx3x |
DEAD-box helicase 3, X-linked |
affects expression |
EXP |
Irinotecan affects the expression of DDX3X mRNA |
CTD |
PMID:20097248 |
|
NCBI chr X:12,152,346...12,165,983
Ensembl chr X:9,479,532...9,493,168
|
|
G |
Ddx5 |
DEAD-box helicase 5 |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of DDX5 mRNA |
CTD |
PMID:32812032 |
|
NCBI chr10:92,224,393...92,231,928
Ensembl chr10:91,723,508...91,732,283
|
|
G |
Dedd |
death effector domain-containing |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DEDD mRNA |
CTD |
PMID:18927307 |
|
NCBI chr13:86,286,341...86,301,789
Ensembl chr13:83,756,108...83,769,332
|
|
G |
Dennd4a |
DENN domain containing 4A |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of DENND4A mRNA; Irinotecan results in decreased expression of DENND4A mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 8:74,218,131...74,331,543
Ensembl chr 8:65,322,941...65,436,330
|
|
G |
Denr |
density regulated reinitiation and release factor |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DENR mRNA |
CTD |
PMID:18927307 |
|
NCBI chr12:38,323,433...38,346,207
Ensembl chr12:32,662,516...32,683,843
|
|
G |
Depdc1b |
DEP domain containing 1B |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DEPDC1B mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:41,605,686...41,697,207
Ensembl chr 2:39,891,481...39,963,779
|
|
G |
Desi2 |
desumoylating isopeptidase 2 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DESI2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr13:92,493,765...92,543,307
Ensembl chr13:89,961,934...90,016,416
|
|
G |
Dffb |
DNA fragmentation factor subunit beta |
increases response to substance |
ISO |
DFFB protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 5:169,804,873...169,817,157
Ensembl chr 5:164,522,463...164,534,628
|
|
G |
Dgcr8 |
DGCR8 microprocessor complex subunit |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DGCR8 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr11:96,208,959...96,241,560
Ensembl chr11:82,704,729...82,737,242
|
|
G |
Dip2a |
disco-interacting protein 2 homolog A |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DIP2A mRNA |
CTD |
PMID:18927307 |
|
NCBI chr20:12,284,566...12,371,068
Ensembl chr20:12,284,654...12,370,217
|
|
G |
Dlc1 |
DLC1 Rho GTPase activating protein |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DLC1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr16:55,246,716...55,671,441
Ensembl chr16:55,291,584...55,671,439
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
affects expression |
EXP |
Irinotecan affects the expression of DLD mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 6:53,631,686...53,655,059
Ensembl chr 6:47,903,914...47,924,795
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
decreases expression multiple interactions |
ISO |
Irinotecan analog results in decreased expression of DLG1 mRNA DLG1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] |
CTD |
PMID:18927307 |
|
NCBI chr11:82,416,853...82,607,797
Ensembl chr11:68,911,883...69,102,689
|
|
G |
Dlx4 |
distal-less homeobox 4 |
increases expression |
ISO |
Irinotecan analog results in increased expression of DLX4 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:80,581,878...80,587,272
Ensembl chr10:80,085,465...80,090,456
|
|
G |
Dmac2l |
distal membrane arm assembly component 2 like |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DMAC2L mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 6:93,941,605...93,959,932
Ensembl chr 6:88,205,700...88,223,933
|
|
G |
Dmwd |
DM1 locus, WD repeat containing |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of DMWD mRNA; Irinotecan results in increased expression of DMWD mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 1:87,850,475...87,857,263
Ensembl chr 1:78,722,330...78,740,593
|
|
G |
Dok6 |
docking protein 6 |
decreases expression |
ISO |
Irinotecan results in decreased expression of DOK6 mRNA |
CTD |
PMID:20185912 |
|
NCBI chr18:82,572,762...83,015,951
Ensembl chr18:82,572,762...83,015,951
|
|
G |
Dph2 |
diphthamide biosynthesis 2 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DPH2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:136,713,868...136,716,828
Ensembl chr 5:131,428,268...131,431,395
|
|
G |
Dph6 |
diphthamine biosynthesis 6 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DPH6 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 3:121,761,495...121,891,727
Ensembl chr 3:101,307,231...101,534,603
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
decreases response to substance decreases expression |
ISO |
DPYD protein results in decreased susceptibility to Irinotecan Irinotecan metabolite results in decreased expression of DPYD mRNA; Irinotecan results in decreased expression of DPYD mRNA |
CTD |
PMID:15956246 PMID:16734730 |
|
NCBI chr 2:209,293,902...210,159,777
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Drd5 |
dopamine receptor D5 |
multiple interactions |
ISO |
DRD5 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] |
CTD |
PMID:17327601 |
|
NCBI chr14:76,700,244...76,703,344
Ensembl chr14:72,489,347...72,490,774
|
|
G |
Drg1 |
developmentally regulated GTP binding protein 1 |
multiple interactions |
ISO |
[selenomethylselenocysteine co-treated with Irinotecan] results in decreased expression of DRG1 |
CTD |
PMID:15897249 |
|
NCBI chr14:78,103,876...78,119,976
Ensembl chr14:78,103,876...78,119,953
|
|
G |
Dst |
dystonin |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of DST mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 9:43,631,716...44,025,535
Ensembl chr 9:36,135,284...36,529,615
|
|
G |
Duox2 |
dual oxidase 2 |
affects expression |
EXP |
Irinotecan affects the expression of DUOX2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 3:129,680,543...129,698,886
Ensembl chr 3:109,226,924...109,245,902
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
EXP |
Irinotecan results in increased expression of DUSP1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr10:17,184,853...17,187,646
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of DUSP2 mRNA; Irinotecan results in increased expression of DUSP2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 3:135,009,636...135,011,821
Ensembl chr 3:114,556,325...114,558,499
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
affects expression |
EXP |
Irinotecan affects the expression of DUSP6 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Dyrk1a |
dual specificity tyrosine phosphorylation regulated kinase 1A |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of DYRK1A mRNA; Irinotecan results in decreased expression of DYRK1A mRNA |
CTD |
PMID:15956246 |
|
NCBI chr11:47,360,824...47,479,033
Ensembl chr11:33,890,490...34,009,420
|
|
G |
Dyrk2 |
dual specificity tyrosine phosphorylation regulated kinase 2 |
decreases expression affects expression |
ISO EXP |
Irinotecan metabolite results in decreased expression of DYRK2 mRNA; Irinotecan results in decreased expression of DYRK2 mRNA Irinotecan affects the expression of DYRK2 mRNA |
CTD |
PMID:15956246 PMID:20097248 |
|
NCBI chr 7:56,235,276...56,265,741
Ensembl chr 7:54,349,610...54,380,106
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
bisindolylmaleimide I inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of EGFR protein]; bisindolylmaleimide I inhibits the reaction [Irinotecan results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein]; Go 6976 inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of EGFR protein]; Go 6976 inhibits the reaction [Irinotecan results in increased phosphorylation of EGFR protein]; Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein; Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein; rottlerin inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of EGFR protein]; rottlerin inhibits the reaction [Irinotecan results in increased phosphorylation of EGFR protein] |
CTD |
PMID:15723263 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO EXP |
Irinotecan metabolite results in increased expression of EGR1 mRNA; Irinotecan results in increased expression of EGR1 mRNA |
CTD |
PMID:15956246 PMID:16280599 PMID:20097248 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2ak4 |
eukaryotic translation initiation factor 2 alpha kinase 4 |
affects expression |
ISO |
Irinotecan analog affects the expression of EIF2AK4 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 3:125,810,207...125,895,574
Ensembl chr 3:105,356,261...105,441,630
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of EIF4E mRNA |
CTD |
PMID:32812032 |
|
NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Elane |
elastase, neutrophil expressed |
multiple interactions increases expression |
ISO |
GSK484 inhibits the reaction [Irinotecan results in increased expression of ELANE mRNA]; phenethyl isothiocyanate inhibits the reaction [Irinotecan results in increased expression of ELANE mRNA] |
CTD |
PMID:38341106 |
|
NCBI chr 7:10,467,877...10,469,725
Ensembl chr 7:9,817,252...9,819,100
|
|
G |
Eml2 |
EMAP like 2 |
multiple interactions |
ISO |
EML2 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] |
CTD |
PMID:17327601 |
|
NCBI chr 1:78,827,595...78,859,342
Ensembl chr 1:78,828,080...78,859,341
|
|
G |
Eml4 |
EMAP like 4 |
affects expression |
EXP |
Irinotecan affects the expression of EML4 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 6:11,219,545...11,334,824
Ensembl chr 6:11,219,566...11,334,879
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ENO1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:166,002,867...166,014,252
Ensembl chr 5:160,719,951...160,731,336 Ensembl chr 3:160,719,951...160,731,336
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of EP300 mRNA; Irinotecan results in decreased expression of EP300 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Eppk1 |
epiplakin 1 |
increases expression |
ISO |
Irinotecan analog results in increased expression of EPPK1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:109,697,607...109,718,468
Ensembl chr 7:107,817,693...107,831,159
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
affects expression |
EXP |
Irinotecan affects the expression of ERBB2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of ERBB4 mRNA; Irinotecan results in increased expression of ERBB4 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 9:76,973,386...78,045,633
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Erc1 |
ELKS/RAB6-interacting/CAST family member 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ERC1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:152,763,664...153,055,724
Ensembl chr 4:152,767,419...153,055,639
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
decreases expression |
ISO |
Irinotecan results in decreased expression of ERCC1 protein |
CTD |
PMID:11593056 |
|
NCBI chr 1:88,099,308...88,135,966
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ereg |
epiregulin |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of EREG mRNA |
CTD |
PMID:18927307 |
|
NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Ets2 |
ETS proto-oncogene 2, transcription factor |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of ETS2 mRNA; Irinotecan results in increased expression of ETS2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr11:48,491,057...48,507,843
Ensembl chr11:35,021,596...35,038,319
|
|
G |
Etv6 |
ETS variant transcription factor 6 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of ETV6 mRNA; Irinotecan results in decreased expression of ETV6 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 4:168,580,405...168,819,817
Ensembl chr 4:166,847,686...167,084,992
|
|
G |
Exoc4 |
exocyst complex component 4 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of EXOC4 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:61,807,706...62,584,316
Ensembl chr 4:61,807,761...62,585,723
|
|
G |
F8 |
coagulation factor VIII |
multiple interactions |
ISO |
F8 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] |
CTD |
PMID:17327601 |
|
NCBI chr18:155,237...187,186
Ensembl chr18:140,955...171,857
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
affects expression |
EXP |
Irinotecan affects the expression of FABP1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:104,744,302...104,753,119
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fabp6 |
fatty acid binding protein 6 |
increases expression |
ISO |
Irinotecan analog results in increased expression of FABP6 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282
|
|
G |
Fam219a |
family with sequence similarity 219, member A |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of FAM219A mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:61,475,185...61,525,749
Ensembl chr 5:56,680,613...56,729,924
|
|
G |
Fam3c |
FAM3 metabolism regulating signaling molecule C |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of FAM3C mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:51,805,686...51,853,030
Ensembl chr 4:50,838,818...50,888,078
|
|
G |
Fancg |
FA complementation group G |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of FANCG mRNA; Irinotecan results in increased expression of FANCG mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 5:57,230,287...57,240,067
Ensembl chr 5:57,231,685...57,240,029
|
|
G |
Farsb |
phenylalanyl-tRNA synthetase subunit beta |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of FARSB mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 9:87,336,321...87,395,546
Ensembl chr 9:79,887,842...79,947,045
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
Irinotecan results in increased expression of and results in increased localization of FAS protein; STAT1 protein promotes the reaction [Irinotecan results in increased localization of FAS protein] Irinotecan results in increased expression of FAS mRNA |
CTD |
PMID:16204068 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
ISO |
[selenomethylselenocysteine co-treated with Irinotecan] results in increased expression of FASLG Irinotecan results in increased expression of FASL protein |
CTD |
PMID:15897249 PMID:21475811 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbxw5 |
F-box and WD repeat domain containing 5 |
increases expression |
ISO |
Irinotecan results in increased expression of FBXW5 mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 3:28,720,670...28,725,237
Ensembl chr 3:8,322,543...8,327,092
|
|
G |
Fcf1 |
Fcf1 rRNA-processing protein |
affects expression |
ISO |
Irinotecan analog affects the expression of FCF1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 6:104,617,780...104,629,643
Ensembl chr 6:104,617,770...104,629,643
|
|
G |
Fcgr2b |
Fc gamma receptor 2B |
increases expression |
EXP |
Irinotecan results in increased expression of FCGR2B mRNA |
CTD |
PMID:20097248 |
|
NCBI chr13:85,725,897...85,740,517
Ensembl chr13:83,193,163...83,207,778
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of FGF2 mRNA; Irinotecan results in increased expression of FGF2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of FGF9 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr15:36,325,552...36,369,995
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgl2 |
fibrinogen-like 2 |
increases expression |
EXP |
Irinotecan results in increased expression of FGL2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:14,602,762...14,608,405
Ensembl chr 4:13,710,575...13,716,207
|
|
G |
Fh |
fumarate hydratase |
affects expression |
EXP |
Irinotecan affects the expression of FH mRNA |
CTD |
PMID:20097248 |
|
NCBI chr13:90,056,565...90,082,450
Ensembl chr13:87,524,337...87,550,266
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
increases expression |
EXP |
Irinotecan results in increased expression of FKBP5 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Fmo5 |
flavin containing dimethylaniline monoxygenase 5 |
affects expression |
EXP |
Irinotecan affects the expression of FMO5 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 2:187,885,741...187,938,468
Ensembl chr 2:185,222,204...185,249,693
|
|
G |
Fn1 |
fibronectin 1 |
increases expression |
ISO |
Irinotecan analog results in increased expression of FN1 mRNA; Irinotecan metabolite results in increased expression of FN1 mRNA; Irinotecan results in increased expression of FN1 mRNA |
CTD |
PMID:15956246 PMID:18927307 |
|
NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression decreases expression |
ISO |
Irinotecan metabolite results in increased expression of FOS mRNA; Irinotecan results in increased expression of FOS mRNA Irinotecan results in decreased expression of FOS mRNA |
CTD |
PMID:15956246 PMID:16432164 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of FOSB mRNA; Irinotecan results in increased expression of FOSB mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Foxa1 |
forkhead box A1 |
affects expression |
EXP |
Irinotecan affects the expression of FOXA1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 6:80,838,380...80,871,195
Ensembl chr 6:75,103,503...75,136,188
|
|
G |
Frk |
fyn-related Src family tyrosine kinase |
affects expression |
EXP |
Irinotecan affects the expression of FRK mRNA |
CTD |
PMID:20097248 |
|
NCBI chr20:38,265,416...38,371,038
Ensembl chr20:38,265,280...38,371,114
|
|
G |
Frmd5 |
FERM domain containing 5 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of FRMD5 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 3:108,492,099...108,763,715
Ensembl chr 3:108,474,562...108,763,498
|
|
G |
Fto |
FTO, alpha-ketoglutarate dependent dioxygenase |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of FTO mRNA |
CTD |
PMID:18927307 |
|
NCBI chr19:31,456,749...31,865,011
Ensembl chr19:15,349,696...15,692,083
|
|
G |
Fxyd3 |
FXYD domain-containing ion transport regulator 3 |
increases expression |
ISO |
Irinotecan results in increased expression of FXYD3 mRNA |
CTD |
PMID:15152939 |
|
NCBI chr 1:95,432,918...95,440,129
|
|
G |
Fyb1 |
FYN binding protein 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of FYB1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:57,360,084...57,508,609
Ensembl chr 2:55,632,698...55,779,629
|
|
G |
G0s2 |
G0/G1switch 2 |
increases expression |
EXP |
Irinotecan results in increased expression of G0S2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451
|
|
G |
G2e3 |
G2/M-phase specific E3 ubiquitin protein ligase |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of G2E3 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 6:68,763,847...68,795,305
Ensembl chr 6:68,764,185...68,793,924
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
EXP |
Irinotecan results in increased expression of GADD45A mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
increases expression |
EXP |
Irinotecan results in increased expression of GADD45G mRNA |
CTD |
PMID:20097248 |
|
NCBI chr17:13,528,606...13,530,351
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Gamt |
guanidinoacetate N-methyltransferase |
affects expression |
EXP |
Irinotecan affects the expression of GAMT mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 7:10,099,267...10,102,083
Ensembl chr 7:9,448,628...9,451,778
|
|
G |
Gata3 |
GATA binding protein 3 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of GATA3 mRNA; Irinotecan results in decreased expression of GATA3 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr17:73,544,234...73,575,670
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gata4 |
GATA binding protein 4 |
affects expression |
EXP |
Irinotecan affects the expression of GATA4 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr15:41,635,572...41,707,252
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gcg |
glucagon |
affects expression |
EXP |
Irinotecan affects the expression of GCG mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 3:67,522,489...67,531,533
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of GDF15 mRNA; Irinotecan results in increased expression of GDF15 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gem |
GTP binding protein overexpressed in skeletal muscle |
increases expression |
EXP |
Irinotecan results in increased expression of GEM mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 5:25,214,309...25,225,222
Ensembl chr 5:25,214,309...25,225,222
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of GGT1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
affects expression increases expression |
ISO EXP |
Irinotecan analog affects the expression of GJA1 mRNA Irinotecan results in increased expression of GJA1 mRNA |
CTD |
PMID:18927307 PMID:20097248 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gk |
glycerol kinase |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of GK mRNA |
CTD |
PMID:18927307 |
|
NCBI chr X:54,106,708...54,189,940
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Gkn1 |
gastrokine 1 |
affects expression |
EXP |
Irinotecan affects the expression of GKN1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:119,790,101...119,795,389
Ensembl chr 4:119,790,101...119,795,389
|
|
G |
Glrx3 |
glutaredoxin 3 |
affects expression |
ISO |
Irinotecan analog affects the expression of GLRX3 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:201,671,410...201,701,722
Ensembl chr 1:192,241,701...192,272,010
|
|
G |
Gna13 |
G protein subunit alpha 13 |
increases expression |
ISO |
Irinotecan analog results in increased expression of GNA13 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:94,837,271...94,870,290
Ensembl chr10:94,337,725...94,370,774
|
|
G |
Gng11 |
G protein subunit gamma 11 |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of GNG11 mRNA |
CTD |
PMID:32812032 |
|
NCBI chr 4:32,977,681...32,983,121
Ensembl chr 4:32,023,003...32,028,442
|
|
G |
Gpatch2l |
G patch domain containing 2-like |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of GPATCH2L mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 6:111,614,344...111,666,603
Ensembl chr 6:105,883,460...105,934,888
|
|
G |
Gpatch4 |
G patch domain containing 4 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of GPATCH4 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:173,499,700...173,520,346
Ensembl chr 2:173,509,897...173,518,684
|
|
G |
Gphn |
gephyrin |
decreases expression |
EXP |
Irinotecan results in decreased expression of GPHN mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 6:102,687,405...103,216,679
Ensembl chr 6:96,892,148...97,483,612
|
|
G |
Gpr183 |
G protein-coupled receptor 183 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of GPR183 mRNA; Irinotecan results in increased expression of GPR183 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr15:105,445,129...105,457,192
Ensembl chr15:99,036,367...99,050,559
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression multiple interactions |
ISO |
Irinotecan results in increased expression of GPT protein phenethyl isothiocyanate inhibits the reaction [Irinotecan results in increased expression of GPT protein] |
CTD |
PMID:38341106 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of GPX3 mRNA; Irinotecan results in increased expression of GPX3 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
increases expression |
EXP |
Irinotecan results in increased expression of GREM1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 3:120,966,639...120,978,319
Ensembl chr 3:100,512,313...100,524,082
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
affects expression |
EXP |
Irinotecan affects the expression of GSTA3 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
affects expression |
EXP |
Irinotecan affects the expression of GSTA4 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 8:87,947,247...87,964,490
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gzmb |
granzyme B |
affects expression |
EXP |
Irinotecan affects the expression of GZMB mRNA |
CTD |
PMID:20097248 |
|
NCBI chr15:34,459,007...34,462,469
Ensembl chr15:30,173,603...30,346,814
|
|
G |
H2ax |
H2A.X variant histone |
increases expression multiple interactions |
ISO |
Irinotecan metabolite results in increased expression of H2AX mRNA; Irinotecan results in increased expression of H2AX mRNA; Irinotecan results in increased expression of H2AX protein [Irinotecan co-treated with rucaparib] results in increased expression of H2AX protein |
CTD |
PMID:15956246 PMID:30612311 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression multiple interactions |
ISO |
Irinotecan metabolite results in increased expression of HBEGF mRNA; Irinotecan results in increased expression of HBEGF mRNA Gefitinib inhibits the reaction [Irinotecan metabolite results in increased expression of HBEGF mRNA]; Gefitinib inhibits the reaction [Irinotecan results in increased expression of HBEGF mRNA] |
CTD |
PMID:15723263 |
|
NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hbg1 |
hemoglobin subunit gamma 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of HBG1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:167,683,760...167,685,315
Ensembl chr 1:158,271,873...158,273,425
|
|
G |
Hcfc1 |
host cell factor C1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of HCFC1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr X:156,839,100...156,864,132
Ensembl chr X:151,687,779...151,712,638
|
|
G |
Hectd2 |
HECT domain E3 ubiquitin protein ligase 2 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of HECTD2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:243,687,248...243,756,069
Ensembl chr 1:234,275,705...234,343,487
|
|
G |
Hells |
helicase, lymphoid specific |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of HELLS mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:246,113,580...246,159,230
Ensembl chr 1:236,701,758...236,746,844
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
increases activity |
ISO |
Irinotecan results in increased activity of HES1 protein |
CTD |
PMID:19147571 |
|
NCBI chr11:84,210,632...84,213,045
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hgfac |
HGF activator |
affects expression |
EXP |
Irinotecan affects the expression of HGFAC mRNA |
CTD |
PMID:20097248 |
|
NCBI chr14:75,707,588...75,714,182
Ensembl chr14:75,707,591...75,714,278
|
|
G |
Hist1h2al1 |
histone cluster 1 H2A family like 1 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of H2AC6 mRNA; Irinotecan results in decreased expression of H2AC6 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr17:47,403,701...47,404,167
|
|
G |
Hk2 |
hexokinase 2 |
affects expression |
EXP |
Irinotecan affects the expression of HK2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of HMMR mRNA; Irinotecan results in decreased expression of HMMR mRNA |
CTD |
PMID:15956246 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Luteolin promotes the reaction [Irinotecan results in increased expression of HMOX1 mRNA] |
CTD |
PMID:34699766 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hmx1 |
H6 family homeobox 1 |
increases expression |
ISO |
Irinotecan results in increased expression of HMX1 mRNA |
CTD |
PMID:20185912 |
|
NCBI chr14:79,585,840...79,589,626
Ensembl chr14:75,361,225...75,364,993
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of HNRNPA1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:136,253,633...136,260,085
Ensembl chr 7:134,375,150...134,381,609
|
|
G |
Hnrnpa3 |
heterogeneous nuclear ribonucleoprotein A3 |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of HNRNPA3 mRNA |
CTD |
PMID:32812032 |
|
NCBI chr 3:80,984,470...80,999,413
Ensembl chr 3:60,578,673...60,588,306
|
|
G |
Hnrnpd |
heterogeneous nuclear ribonucleoprotein D |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of HNRNPD mRNA |
CTD |
PMID:18927307 |
|
NCBI chr14:9,918,630...9,938,072
Ensembl chr14:9,615,479...9,633,786
|
|
G |
Hnrnpdl |
heterogeneous nuclear ribonucleoprotein D-like |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of HNRNPDL mRNA |
CTD |
PMID:18927307 |
|
NCBI chr14:9,861,716...9,867,945
Ensembl chr14:9,557,425...9,562,506
|
|
G |
Hrg |
histidine-rich glycoprotein |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of HRG mRNA; Irinotecan results in increased expression of HRG mRNA |
CTD |
PMID:15956246 |
|
NCBI chr11:91,559,087...91,573,982
Ensembl chr11:78,054,498...78,069,389
|
|
G |
Hs3st3b1 |
heparan sulfate-glucosamine 3-sulfotransferase 3B1 |
increases expression |
ISO |
Irinotecan analog results in increased expression of HS3ST3B1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:48,561,473...48,593,970
Ensembl chr10:48,561,473...48,593,970
|
|
G |
Hspa4l |
heat shock protein family A (Hsp70) member 4 like |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of HSPA4L mRNA; Irinotecan results in decreased expression of HSPA4L mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 2:125,668,346...125,726,404
Ensembl chr 2:123,740,384...123,793,084
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in increased expression of HTATIP2 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629
|
|
G |
Hypk |
Huntingtin interacting protein K |
affects expression |
ISO |
Irinotecan analog affects the expression of HYPK mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 3:128,888,709...128,890,089
Ensembl chr 3:108,432,539...108,436,370
|
|
G |
Ibtk |
inhibitor of Bruton tyrosine kinase |
decreases expression |
ISO |
Irinotecan results in decreased expression of IBTK mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 8:95,505,630...95,579,435
Ensembl chr 8:86,625,597...86,698,260
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of ID2 mRNA; Irinotecan results in decreased expression of ID2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 6:47,469,162...47,470,995
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Ier3 |
immediate early response 3 |
increases expression |
ISO |
Irinotecan results in increased expression of IER3 mRNA |
CTD |
PMID:20185912 |
|
NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Ifi27l2a |
interferon, alpha-inducible protein 27 like 2A |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in increased expression of IFI27L2 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr 6:128,363,658...128,365,144
Ensembl chr 6:122,598,872...122,600,360
|
|
G |
Ifitm1 |
interferon induced transmembrane protein 1 |
increases expression |
EXP ISO |
Irinotecan results in increased expression of IFITM1 mRNA Irinotecan analog results in increased expression of IFITM1 mRNA |
CTD |
PMID:18927307 PMID:20097248 |
|
NCBI chr 1:205,496,757...205,498,796
Ensembl chr 1:196,067,963...196,069,169
|
|
G |
Ifitm3 |
interferon induced transmembrane protein 3 |
increases expression |
EXP |
Irinotecan results in increased expression of IFITM3 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 1:205,540,649...205,541,758
Ensembl chr 1:196,111,043...196,112,203
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases expression |
EXP |
Ciprofloxacin inhibits the reaction [Irinotecan promotes the reaction [Mitogens results in increased expression of IFNG protein]]; Irinotecan inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein]; Irinotecan inhibits the reaction [Mitogens results in increased expression of IFNG protein]; Irinotecan promotes the reaction [Mitogens results in increased expression of IFNG protein]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of IFNG protein]; Thalidomide promotes the reaction [Irinotecan results in increased expression of IFNG protein] |
CTD |
PMID:16815871 PMID:19401694 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of IGF1 mRNA; Irinotecan results in increased expression of IGF1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
increases expression |
EXP |
Irinotecan results in increased expression of IGFBP5 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Ighg1 |
immunoglobulin heavy constant gamma 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of IGHG1 mRNA |
CTD |
PMID:18927307 |
|
Ensembl chr 6:132,389,370...132,393,397
|
|
G |
Il10 |
interleukin 10 |
multiple interactions decreases secretion |
ISO EXP |
Deoxycholic Acid promotes the reaction [Irinotecan results in decreased secretion of IL10 protein]; Taurodeoxycholic Acid promotes the reaction [Irinotecan results in decreased secretion of IL10 protein] Ciprofloxacin inhibits the reaction [Irinotecan inhibits the reaction [Mitogens results in increased expression of IL10 protein]]; Irinotecan inhibits the reaction [Mitogens results in increased expression of IL10 protein] |
CTD |
PMID:19401694 PMID:26706406 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il13ra1 |
interleukin 13 receptor subunit alpha 1 |
affects expression |
EXP |
Irinotecan affects the expression of IL13RA1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr X:120,213,670...120,294,777
Ensembl chr X:115,348,860...115,408,681 Ensembl chr11:115,348,860...115,408,681
|
|
G |
Il15 |
interleukin 15 |
affects expression |
EXP |
Irinotecan affects the expression of IL15 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr19:42,536,160...42,611,349
Ensembl chr19:25,640,251...25,706,820
|
|
G |
Il17a |
interleukin 17A |
increases expression |
ISO |
Irinotecan results in increased expression of IL17A mRNA; Irinotecan results in increased expression of IL17A protein |
CTD |
PMID:26431797 |
|
NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il18 |
interleukin 18 |
increases expression multiple interactions |
ISO |
Irinotecan results in increased expression of IL18 mRNA; Irinotecan results in increased expression of IL18 protein [Irinotecan co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL18 protein; [Irinotecan co-treated with Lipopolysaccharides] results in increased expression of IL18 mRNA; EVP 4593 inhibits the reaction [Irinotecan results in increased expression of and results in increased secretion of IL18 protein]; pyrazolanthrone inhibits the reaction [Irinotecan results in increased expression of and results in increased secretion of IL18 protein] [Fluorouracil co-treated with Irinotecan] results in decreased expression of IL18 mRNA; [Irinotecan co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL18 protein; [Irinotecan co-treated with Lipopolysaccharides] results in increased expression of IL18 mRNA; EVP 4593 inhibits the reaction [[Lipopolysaccharides co-treated with Irinotecan] results in increased expression of and results in increased secretion of IL18 protein]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides co-treated with Irinotecan] results in increased expression of and results in increased secretion of IL18 protein] |
CTD |
PMID:16391804 PMID:26431797 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression affects expression increases secretion |
ISO EXP |
[Irinotecan co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein; [Irinotecan co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA; EVP 4593 inhibits the reaction [[Lipopolysaccharides co-treated with Irinotecan] results in increased expression of and results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of IL1B mRNA]; Luteolin inhibits the reaction [Irinotecan results in increased secretion of IL1B protein]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides co-treated with Irinotecan] results in increased expression of and results in increased secretion of IL1B protein] Ciprofloxacin inhibits the reaction [Irinotecan inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; Irinotecan inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of IL1B protein]; Thalidomide promotes the reaction [Irinotecan results in increased expression of IL1B protein] Irinotecan results in increased expression of IL1B mRNA; Irinotecan results in increased expression of IL1B protein 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [carvacrol inhibits the reaction [Irinotecan results in increased expression of IL1B protein]]; [Irinotecan co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein; [Irinotecan co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA; carvacrol inhibits the reaction [Irinotecan results in increased expression of IL1B protein]; Irinotecan results in increased expression of and results in increased cleavage of and results in increased secretion of IL1B protein; MYD88 protein affects the reaction [Irinotecan affects the expression of IL1B mRNA]; phenethyl isothiocyanate inhibits the reaction [Irinotecan results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [Irinotecan results in increased expression of IL1B protein]; TLR2 protein affects the reaction [Irinotecan affects the expression of IL1B mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of IL1B mRNA] Irinotecan metabolite results in increased expression of IL1B mRNA; Irinotecan results in increased expression of IL1B mRNA Irinotecan affects the expression of IL1B protein |
CTD |
PMID:15956246 PMID:16815871 PMID:18535404 PMID:19401694 PMID:26431797 PMID:27838229 PMID:28454924 PMID:34699766 PMID:35728726 PMID:38341106 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
decreases expression multiple interactions |
EXP |
Irinotecan results in decreased expression of IL2 protein Ciprofloxacin inhibits the reaction [Irinotecan promotes the reaction [Mitogens results in increased expression of IL2 protein]]; Irinotecan inhibits the reaction [Mitogens results in increased expression of IL2 protein]; Irinotecan promotes the reaction [Mitogens results in increased expression of IL2 protein]; Thalidomide inhibits the reaction [Irinotecan results in decreased expression of IL2 protein]; Thalidomide promotes the reaction [Irinotecan results in decreased expression of IL2 protein] |
CTD |
PMID:16815871 PMID:19401694 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il33 |
interleukin 33 |
increases expression increases secretion multiple interactions |
ISO |
Irinotecan results in increased expression of IL33 mRNA Irinotecan results in increased secretion of IL33 protein Luteolin inhibits the reaction [Irinotecan results in increased expression of IL33 mRNA]; Luteolin inhibits the reaction [Irinotecan results in increased secretion of IL33 protein]; Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of IL33 mRNA]; Rosiglitazone inhibits the reaction [Irinotecan results in increased secretion of IL33 protein] |
CTD |
PMID:34699766 |
|
NCBI chr 1:237,115,478...237,149,897
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions decreases response to substance |
ISO EXP |
Irinotecan results in increased expression of IL6 mRNA; Irinotecan results in increased expression of IL6 protein Ciprofloxacin inhibits the reaction [Irinotecan inhibits the reaction [Mitogens results in increased expression of IL6 protein]]; Ciprofloxacin inhibits the reaction [Irinotecan promotes the reaction [Mitogens results in increased expression of IL6 protein]]; Irinotecan inhibits the reaction [Mitogens results in increased expression of IL6 protein]; Irinotecan promotes the reaction [Mitogens results in increased expression of IL6 protein]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of IL6 protein] IL6 protein results in decreased susceptibility to Irinotecan MYD88 protein affects the reaction [Irinotecan results in increased expression of IL6 mRNA]; Silymarin inhibits the reaction [Irinotecan results in increased expression of IL6 protein]; TLR2 protein affects the reaction [Irinotecan results in increased expression of IL6 mRNA]; TLR4 protein affects the reaction [Irinotecan results in increased expression of IL6 mRNA] |
CTD |
PMID:16815871 PMID:17537833 PMID:18535404 PMID:19401694 PMID:26431797 PMID:28454924 PMID:35728726 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Immp2l |
inner mitochondrial membrane peptidase subunit 2 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of IMMP2L mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 6:63,797,189...64,696,906
Ensembl chr 6:58,070,283...58,969,840
|
|
G |
Immt |
inner membrane mitochondrial protein |
affects expression |
ISO |
Irinotecan analog affects the expression of IMMT mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:105,438,657...105,477,370
Ensembl chr 4:103,880,459...103,919,109
|
|
G |
Ing3 |
inhibitor of growth family, member 3 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ING3 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:50,477,954...50,505,168
Ensembl chr 4:50,477,962...50,503,715
|
|
G |
Insig1 |
insulin induced gene 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of INSIG1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Itga2 |
integrin subunit alpha 2 |
increases expression |
ISO |
Irinotecan analog results in increased expression of ITGA2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:48,253,412...48,354,509
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itgae |
integrin subunit alpha E |
increases response to substance |
ISO |
ITGAE protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr10:57,704,813...57,764,093
Ensembl chr10:57,591,753...57,764,093 Ensembl chr10:57,591,753...57,764,093
|
|
G |
Itgav |
integrin subunit alpha V |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of ITGAV mRNA; Irinotecan results in decreased expression of ITGAV mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 3:89,245,382...89,333,512
Ensembl chr 3:68,838,189...68,926,639
|
|
G |
Itgax |
integrin subunit alpha X |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of ITGAX mRNA; Irinotecan results in increased expression of ITGAX mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 1:192,140,089...192,171,151
Ensembl chr 1:182,719,609...182,740,698
|
|
G |
Itgb3bp |
integrin subunit beta 3 binding protein |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of ITGB3BP mRNA; Irinotecan results in decreased expression of ITGB3BP mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 5:114,460,217...114,525,538
Ensembl chr 5:114,460,221...114,525,704
|
|
G |
Jchain |
joining chain of multimeric IgA and IgM |
affects expression |
EXP |
Irinotecan affects the expression of JCHAIN mRNA |
CTD |
PMID:20097248 |
|
NCBI chr14:19,822,976...19,831,072
Ensembl chr14:19,538,952...19,546,298
|
|
G |
Jpt1 |
Jupiter microtubule associated homolog 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of JPT1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:101,243,428...101,261,464
Ensembl chr10:100,686,797...100,784,513
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP ISO |
Irinotecan results in increased expression of JUN mRNA Irinotecan metabolite results in increased expression of JUN mRNA; Irinotecan results in increased expression of JUN mRNA |
CTD |
PMID:15956246 PMID:20097248 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kansl1 |
KAT8 regulatory NSL complex subunit 1 |
multiple interactions |
ISO |
KANSL1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] |
CTD |
PMID:18927307 |
|
NCBI chr10:89,737,637...89,868,620
Ensembl chr10:89,237,667...89,366,951
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
increases expression |
ISO |
Irinotecan analog results in increased expression of KAT2B mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,562,288...6,667,064
|
|
G |
Kcnj8 |
potassium inwardly-rectifying channel, subfamily J, member 8 |
increases expression |
EXP |
Irinotecan results in increased expression of KCNJ8 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:177,240,692...177,246,548
Ensembl chr 4:175,508,912...175,515,603
|
|
G |
Khdrbs1 |
KH RNA binding domain containing, signal transduction associated 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of KHDRBS1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:147,337,048...147,374,604
Ensembl chr 5:142,063,570...142,089,180
|
|
G |
Kiaa0040 |
KIAA0040 ortholog |
increases expression |
ISO |
Irinotecan analog results in increased expression of KIAA0040 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr13:72,274,519...72,312,103
Ensembl chr13:72,274,552...72,312,103
|
|
G |
Kif14 |
kinesin family member 14 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of KIF14 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr13:50,478,646...50,542,256
Ensembl chr13:47,927,044...47,989,164
|
|
G |
Klf4 |
KLF transcription factor 4 |
increases expression |
ISO |
Irinotecan analog results in increased expression of KLF4 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klf9 |
KLF transcription factor 9 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of KLF9 mRNA; Irinotecan results in increased expression of KLF9 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 1:230,126,646...230,151,641
Ensembl chr 1:220,700,108...220,725,037
|
|
G |
Klhl24 |
kelch-like family member 24 |
increases expression |
ISO |
Irinotecan analog results in increased expression of KLHL24 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr11:94,348,024...94,382,085
Ensembl chr11:80,846,755...80,877,636
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in decreased expression of KNG1 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr11:91,317,354...91,340,148
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Knstrn |
kinetochore-localized astrin/SPAG5 binding protein |
decreases expression |
EXP |
Irinotecan results in decreased expression of KNSTRN mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 3:105,800,762...105,820,555
Ensembl chr 3:105,800,954...105,820,715
|
|
G |
Krit1 |
KRIT1, ankyrin repeat containing |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of KRIT1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:31,253,918...31,288,066
Ensembl chr 4:30,299,203...30,333,359
|
|
G |
Krt18 |
keratin 18 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan co-treated with Vorinostat] results in increased cleavage of KRT18 protein |
CTD |
PMID:15754201 |
|
NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:133,157,475...133,161,166 Ensembl chr10:133,157,475...133,161,166
|
|
G |
Krt5 |
keratin 5 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of KRT5 mRNA; Irinotecan results in decreased expression of KRT5 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 7:134,724,840...134,730,569
Ensembl chr 7:132,846,136...132,851,850
|
|
G |
Lbh |
LBH regulator of WNT signaling pathway |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of LBH mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 6:22,569,238...22,593,056
Ensembl chr 6:22,568,834...22,593,079
|
|
G |
Lgals8 |
galectin 8 |
multiple interactions |
ISO |
LGALS8 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] |
CTD |
PMID:17327601 |
|
NCBI chr17:62,716,368...62,744,272
Ensembl chr17:58,028,105...58,052,764
|
|
G |
Lmf1 |
lipase maturation factor 1 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in increased expression of LMF1 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr10:14,597,726...14,684,071
Ensembl chr10:14,597,594...14,684,119
|
|
G |
Lmo7 |
LIM domain 7 |
affects expression |
EXP |
Irinotecan affects the expression of LMO7 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr15:78,566,999...78,769,833
Ensembl chr15:78,567,023...78,769,783
|
|
G |
Loxl3 |
lysyl oxidase-like 3 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of LOXL3 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:115,540,640...115,556,958
Ensembl chr 4:115,540,685...115,557,466
|
|
G |
Lpcat1 |
lysophosphatidylcholine acyltransferase 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of LPCAT1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:31,594,621...31,644,946
Ensembl chr 1:29,766,071...29,816,401
|
|
G |
Lrch3 |
leucine rich repeats and calponin homology domain containing 3 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of LRCH3 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr11:67,772,499...67,872,269
Ensembl chr11:67,772,506...67,872,264
|
|
G |
Lsm7 |
LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated |
increases response to substance |
ISO |
LSM7 protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 7:8,856,698...8,859,113
Ensembl chr 7:8,856,489...8,859,119
|
|
G |
Ltf |
lactotransferrin |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of LTF mRNA; Irinotecan results in decreased expression of LTF mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 8:119,878,344...119,901,189
Ensembl chr 8:110,999,948...111,022,795
|
|
G |
Ltv1 |
LTV1 ribosome biogenesis factor |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of LTV1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:9,385,834...9,398,557
Ensembl chr 1:7,565,669...7,578,563
|
|
G |
Lyz2 |
lysozyme 2 |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of LYZ2 mRNA |
CTD |
PMID:32812032 |
|
NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mad2l1 |
mitotic arrest deficient 2 like 1 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of MAD2L1 mRNA; Irinotecan results in decreased expression of MAD2L1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 4:97,236,419...97,247,603
Ensembl chr 4:95,906,817...95,913,470
|
|
G |
Maf |
MAF bZIP transcription factor |
affects expression |
EXP |
Irinotecan affects the expression of MAF mRNA |
CTD |
PMID:20097248 |
|
NCBI chr19:60,259,200...60,622,145
Ensembl chr19:43,360,342...43,712,365
|
|
G |
Magi1 |
membrane associated guanylate kinase, WW and PDZ domain containing 1 |
decreases expression |
EXP |
Irinotecan results in decreased expression of MAGI1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:127,762,590...128,368,228
Ensembl chr 4:126,206,816...126,811,691
|
|
G |
Mal |
mal, T-cell differentiation protein |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of MAL mRNA; Irinotecan results in increased expression of MAL mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 3:114,864,378...114,888,136
Ensembl chr 3:114,864,378...114,888,136
|
|
G |
Mall |
mal, T-cell differentiation protein-like |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of MALL mRNA; Irinotecan results in increased expression of MALL mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 3:114,927,897...114,950,840
Ensembl chr 3:114,927,897...114,950,785
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of MAP3K5 mRNA; Irinotecan results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 1:16,505,387...16,723,899
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Map3k6 |
mitogen-activated protein kinase kinase kinase 6 |
increases expression |
EXP |
Irinotecan results in increased expression of MAP3K6 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 5:150,724,029...150,736,113
Ensembl chr 5:145,440,346...145,452,212
|
|
G |
Map4k3 |
mitogen-activated protein kinase kinase kinase kinase 3 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of MAP4K3 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 6:20,029,246...20,198,583
Ensembl chr 6:14,277,121...14,446,334
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases expression |
ISO EXP |
Irinotecan results in increased phosphorylation of and results in increased activity of MAPK1 protein Irinotecan results in increased expression of MAPK1 mRNA |
CTD |
PMID:16432164 PMID:20097248 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk13 |
mitogen activated protein kinase 13 |
affects expression |
EXP |
Irinotecan affects the expression of MAPK13 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr20:6,835,277...6,845,500
Ensembl chr20:6,835,320...6,844,222
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Irinotecan results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:16432164 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Marchf6 |
membrane associated ring-CH-type finger 6 |
increases expression |
ISO |
Irinotecan analog results in increased expression of MARCHF6 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:84,166,570...84,243,817
Ensembl chr 2:82,455,689...82,532,910
|
|
G |
Matn2 |
matrilin 2 |
increases expression |
ISO |
Irinotecan analog results in increased expression of MATN2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:67,380,140...67,529,767
Ensembl chr 7:65,494,834...65,645,113
|
|
G |
Matr3 |
matrin 3 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of MATR3 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr18:27,428,190...27,474,421
Ensembl chr18:27,163,714...27,193,166
|
|
G |
Mbnl1 |
muscleblind-like splicing regulator 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of MBNL1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:146,789,570...146,964,136
Ensembl chr 2:144,670,285...144,814,368
|
|
G |
Mbp |
myelin basic protein |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of MBP mRNA |
CTD |
PMID:18927307 |
|
NCBI chr18:78,130,652...78,241,174
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mccc2 |
methylcrotonyl-CoA carboxylase subunit 2 |
decreases expression multiple interactions |
ISO |
Irinotecan analog results in decreased expression of MCCC2 mRNA MCCC2 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] |
CTD |
PMID:18927307 |
|
NCBI chr 2:33,039,044...33,110,092
Ensembl chr 2:31,304,932...31,375,972
|
|
G |
Mcf2l |
MCF.2 cell line derived transforming sequence-like |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of MCF2L mRNA; Irinotecan results in decreased expression of MCF2L mRNA |
CTD |
PMID:15956246 |
|
NCBI chr16:83,209,277...83,355,683
Ensembl chr16:76,507,133...76,652,733
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases response to substance |
ISO |
MCL1 protein results in decreased susceptibility to Irinotecan |
CTD |
PMID:21507240 |
|
NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mcm4 |
minichromosome maintenance complex component 4 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of MCM4 mRNA; Irinotecan results in decreased expression of MCM4 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr11:98,762,599...98,776,300
Ensembl chr11:85,258,443...85,272,144
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of MDM2 mRNA; Irinotecan results in increased expression of MDM2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mdn1 |
midasin AAA ATPase 1 |
affects expression |
ISO |
Irinotecan analog affects the expression of MDN1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:51,851,785...51,982,688
Ensembl chr 5:47,055,447...47,186,332
|
|
G |
Med13 |
mediator complex subunit 13 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of MED13 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:71,584,354...71,674,614
Ensembl chr10:71,090,516...71,177,242
|
|
G |
Mef2b |
myocyte enhancer factor 2B |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of MEF2B mRNA; Irinotecan results in increased expression of MEF2B mRNA |
CTD |
PMID:15956246 |
|
NCBI chr16:19,286,951...19,305,547
Ensembl chr16:19,253,010...19,268,967
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases expression increases response to substance |
ISO |
Irinotecan metabolite results in decreased expression of MGMT mRNA MGMT mRNA results in increased susceptibility to Irinotecan |
CTD |
PMID:15239142 PMID:18492797 |
|
NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Minpp1 |
multiple inositol-polyphosphate phosphatase 1 |
affects expression |
EXP |
Irinotecan affects the expression of MINPP1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 1:230,354,483...230,379,730
Ensembl chr 1:230,354,438...230,379,730
|
|
G |
Mip |
major intrinsic protein of lens fiber |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of MIP mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:1,228,089...1,237,707
Ensembl chr 7:647,315...654,400
|
|
G |
Mir128-1 |
microRNA 128-1 |
increases expression |
ISO |
Irinotecan results in increased expression of MIR128-1 mRNA |
CTD |
PMID:22898888 |
|
NCBI chr13:42,251,884...42,251,965
Ensembl chr13:39,699,449...39,699,530
|
|
G |
Mir34a |
microRNA 34a |
increases expression |
ISO |
Irinotecan results in increased expression of MIR34A mRNA |
CTD |
PMID:22898888 |
|
NCBI chr 5:165,815,952...165,816,053
Ensembl chr 5:160,533,002...160,533,103
|
|
G |
Mir449a |
microRNA 449a |
increases expression |
ISO |
Irinotecan results in increased expression of MIR449A mRNA |
CTD |
PMID:22898888 |
|
NCBI chr 2:44,670,714...44,670,804
Ensembl chr 2:44,670,714...44,670,804
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Irinotecan co-treated with rucaparib] results in decreased expression of MKI67 protein |
CTD |
PMID:30612311 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mkx |
mohawk homeobox |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of MKX mRNA |
CTD |
PMID:18927307 |
|
NCBI chr17:59,772,113...59,851,160
Ensembl chr17:55,077,540...55,156,124
|
|
G |
Mlh1 |
mutL homolog 1 |
affects response to substance |
ISO |
MLH1 protein affects the susceptibility to Irinotecan |
CTD |
PMID:18949393 |
|
NCBI chr 8:120,074,871...120,112,109
Ensembl chr 8:111,196,468...111,233,617
|
|
G |
Mlxipl |
MLX interacting protein-like |
affects expression |
EXP |
Irinotecan affects the expression of MLXIPL mRNA |
CTD |
PMID:20097248 |
|
NCBI chr12:27,178,158...27,213,675
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; Irinotecan results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein |
CTD |
PMID:36191607 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
ISO |
Irinotecan metabolite results in increased expression of MMP9 mRNA; Irinotecan results in increased expression of MMP9 mRNA [Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased expression of MMP9 protein; Irinotecan results in decreased secretion of and results in decreased activity of and affects the expression of MMP9 protein |
CTD |
PMID:15956246 PMID:36191607 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases expression increases activity increases expression |
ISO |
2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [carvacrol inhibits the reaction [Irinotecan results in increased activity of MPO protein]]; carvacrol inhibits the reaction [Irinotecan results in increased activity of MPO protein]; GSK484 inhibits the reaction [Irinotecan results in increased activity of MPO protein]; GSK484 inhibits the reaction [Irinotecan results in increased expression of MPO mRNA]; phenethyl isothiocyanate inhibits the reaction [Irinotecan results in increased activity of MPO protein]; phenethyl isothiocyanate inhibits the reaction [Irinotecan results in increased expression of MPO mRNA] Irinotecan metabolite results in decreased expression of MPO mRNA; Irinotecan results in decreased expression of MPO mRNA [Irinotecan co-treated with Dimethyl Sulfoxide] results in increased activity of MPO protein; Irinotecan promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Dimethyl Sulfoxide] results in increased activity of MPO protein] |
CTD |
PMID:15956246 PMID:27838229 PMID:38341106 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mpp7 |
MAGUK p55 scaffold protein 7 |
increases expression |
ISO |
Irinotecan analog results in increased expression of MPP7 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr17:60,135,096...60,401,814
Ensembl chr17:55,442,696...55,706,748
|
|
G |
Mpst |
mercaptopyruvate sulfurtransferase |
decreases expression |
ISO |
Irinotecan results in decreased expression of MPST mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 7:109,955,581...109,963,155
Ensembl chr 7:109,955,675...109,963,141
|
|
G |
Mrps30 |
mitochondrial ribosomal protein S30 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of MRPS30 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:50,456,253...50,463,128
Ensembl chr 2:50,456,255...50,463,105
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression affects response to substance |
ISO |
Irinotecan metabolite results in decreased expression of MSH2 mRNA; Irinotecan results in decreased expression of MSH2 mRNA MSH2 protein affects the susceptibility to Irinotecan |
CTD |
PMID:15956246 PMID:18949393 |
|
NCBI chr 6:12,567,368...12,626,534
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
increases expression |
EXP |
Irinotecan results in increased expression of MSR1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr16:59,421,250...59,507,070
Ensembl chr16:52,717,732...52,799,676
|
|
G |
Mt-atp6 |
mitochondrially encoded ATP synthase membrane subunit 6 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in increased expression of ATP6 mRNA |
CTD |
PMID:16391804 |
|
Ensembl chr MT:7,919...8,599
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
EXP |
Irinotecan results in increased expression of MT1A mRNA |
CTD |
PMID:20097248 |
|
NCBI chr19:10,831,959...10,832,975
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Mthfd1l |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of MTHFD1L mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:42,849,424...43,038,313
Ensembl chr 1:40,444,008...40,632,905
|
|
G |
Mthfs |
methenyltetrahydrofolate synthetase |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of MTHFS mRNA; Irinotecan results in decreased expression of MTHFS mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 8:98,609,410...98,681,901
Ensembl chr 8:89,729,508...89,799,089
|
|
G |
Mtmr4 |
myotubularin related protein 4 |
affects expression |
EXP |
Irinotecan affects the expression of MTMR4 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr10:72,890,665...72,913,598
Ensembl chr10:72,392,551...72,416,342
|
|
G |
Mx2 |
MX dynamin like GTPase 2 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of MX2 mRNA; Irinotecan results in decreased expression of MX2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr11:50,375,101...50,399,373
Ensembl chr11:36,906,111...36,930,342
|
|
G |
Myb |
MYB proto-oncogene, transcription factor |
increases response to substance |
ISO |
MYB protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 1:17,759,309...17,793,306
Ensembl chr 1:15,939,761...15,973,057
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions affects response to substance |
ISO |
MYD88 protein affects the reaction [Irinotecan affects the expression of IL1B mRNA]; MYD88 protein affects the reaction [Irinotecan affects the expression of NR1I2 mRNA]; MYD88 protein affects the reaction [Irinotecan affects the expression of NR1I3 mRNA]; MYD88 protein affects the reaction [Irinotecan affects the expression of TNF mRNA]; MYD88 protein affects the reaction [Irinotecan results in decreased expression of UGT1A1 mRNA]; MYD88 protein affects the reaction [Irinotecan results in increased expression of IL6 mRNA] MYD88 protein affects the susceptibility to Irinotecan |
CTD |
PMID:35728726 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Myh10 |
myosin heavy chain 10 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of MYH10 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:53,891,955...54,024,032
Ensembl chr10:53,394,389...53,525,165
|
|
G |
Mysm1 |
myb-like, SWIRM and MPN domains 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of MYSM1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:114,877,112...114,981,463
Ensembl chr 5:109,776,286...109,819,967
|
|
G |
N4bp1 |
Nedd4 binding protein 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of N4BP1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr19:36,396,082...36,446,835
Ensembl chr19:20,222,776...20,273,570
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of NCF1 mRNA |
CTD |
PMID:32812032 |
|
NCBI chr12:28,121,816...28,131,080
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Nck1 |
NCK adaptor protein 1 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of NCK1 mRNA; Irinotecan results in decreased expression of NCK1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 8:109,897,723...109,958,247
Ensembl chr 8:101,018,702...101,079,300
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of NCOA1 mRNA; Irinotecan results in increased expression of NCOA1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 6:32,952,090...33,229,829
Ensembl chr 6:27,232,611...27,475,664
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions decreases expression |
ISO |
NCOR1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] Irinotecan analog results in decreased expression of NCOR1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:47,498,852...47,641,612
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Ncstn |
nicastrin |
affects response to substance |
ISO |
NCSTN protein affects the susceptibility to Irinotecan |
CTD |
PMID:19147571 |
|
NCBI chr13:87,062,827...87,078,839
Ensembl chr13:84,530,440...84,546,454
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
decreases response to substance |
ISO |
NDRG1 protein results in decreased susceptibility to Irinotecan |
CTD |
PMID:15867226 |
|
NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Nek2 |
NIMA-related kinase 2 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of NEK2 mRNA; Irinotecan results in decreased expression of NEK2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions |
ISO |
Irinotecan results in increased expression of NFE2L2 mRNA Luteolin inhibits the reaction [Irinotecan results in increased expression of NFE2L2 mRNA]; PPARG protein affects the reaction [Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NFE2L2 mRNA]]; Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:34699766 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression increases activity multiple interactions |
EXP ISO |
Irinotecan results in increased expression of NFKB1 mRNA Irinotecan results in increased activity of NFKB1 protein Irinotecan results in increased expression of NFKB1 protein carvacrol inhibits the reaction [Irinotecan results in increased expression of NFKB1 protein]; Silymarin inhibits the reaction [Irinotecan results in increased expression of NFKB1 protein] |
CTD |
PMID:18182997 PMID:20097248 PMID:27838229 PMID:28454924 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression multiple interactions increases response to substance |
EXP ISO |
Irinotecan results in increased expression of NFKBIA mRNA AS602868 inhibits the reaction [Irinotecan results in increased phosphorylation of and results in decreased expression of NFKBIA protein]; Irinotecan results in increased phosphorylation of and results in decreased expression of NFKBIA protein NFKBIA gene mutant form results in increased susceptibility to Irinotecan |
CTD |
PMID:12675310 PMID:18182997 PMID:20097248 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nherf2 |
NHERF family PDZ scaffold protein 2 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of NHERF2 mRNA; Irinotecan results in increased expression of NHERF2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr10:13,662,461...13,672,975
Ensembl chr10:13,662,461...13,673,049
|
|
G |
Nid1 |
nidogen 1 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of NID1 mRNA; Irinotecan results in increased expression of NID1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr17:93,069,013...93,142,416
Ensembl chr17:86,085,077...86,158,267
|
|
G |
Nmu |
neuromedin U |
affects expression |
EXP |
Irinotecan affects the expression of NMU mRNA |
CTD |
PMID:20097248 |
|
NCBI chr14:32,198,789...32,226,397
Ensembl chr14:31,844,728...31,872,192
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
ISO |
Irinotecan results in increased expression of NOS2 mRNA Luteolin inhibits the reaction [Irinotecan results in increased expression of NOS2 mRNA]; Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NOS2 mRNA] GSK484 inhibits the reaction [Irinotecan results in increased expression of NOS2 mRNA]; phenethyl isothiocyanate inhibits the reaction [Irinotecan results in increased expression of NOS2 mRNA] |
CTD |
PMID:34699766 PMID:38341106 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression multiple interactions increases expression |
ISO |
Irinotecan analog results in decreased expression of NQO1 mRNA Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]]; PPARG protein affects the reaction [Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]]; Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA] |
CTD |
PMID:18927307 PMID:34699766 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions affects expression |
ISO |
MYD88 protein affects the reaction [Irinotecan affects the expression of NR1I2 mRNA]; TLR2 protein affects the reaction [Irinotecan affects the expression of NR1I2 mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of NR1I2 mRNA] |
CTD |
PMID:35728726 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
affects expression multiple interactions |
ISO |
Irinotecan affects the expression of NR1I3 mRNA MYD88 protein affects the reaction [Irinotecan affects the expression of NR1I3 mRNA]; TLR2 protein affects the reaction [Irinotecan affects the expression of NR1I3 mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of NR1I3 mRNA] |
CTD |
PMID:35728726 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
decreases response to substance |
ISO |
NR3C1 protein results in decreased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
affects expression |
EXP |
Irinotecan affects the expression of NR3C2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr19:47,619,853...47,964,089
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Nrip1 |
nuclear receptor interacting protein 1 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in increased expression of NRIP1 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr11:28,382,835...28,466,483
Ensembl chr11:14,895,553...14,981,761
|
|
G |
Ns5atp4 |
NS5A transactivated protein 4 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of C1ORF43 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:177,792,070...177,804,943
Ensembl chr 2:175,494,304...175,510,663
|
|
G |
Nsf |
N-ethylmaleimide sensitive factor, vesicle fusing ATPase |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of NSF mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:88,727,912...88,857,375
Ensembl chr10:88,727,912...88,857,386
|
|
G |
Nsmaf |
neutral sphingomyelinase activation associated factor |
decreases expression |
ISO |
Irinotecan results in decreased expression of NSMAF mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 5:19,517,795...19,578,773
Ensembl chr 5:19,518,348...19,577,627
|
|
G |
Nup153 |
nucleoporin 153 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of NUP153 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr17:18,178,434...18,231,109
Ensembl chr17:17,972,217...18,024,876
|
|
G |
Nusap1 |
nucleolar and spindle associated protein 1 |
decreases expression |
ISO EXP |
Irinotecan analog results in decreased expression of NUSAP1 mRNA Irinotecan results in decreased expression of NUSAP1 mRNA |
CTD |
PMID:18927307 PMID:20097248 |
|
NCBI chr 3:127,057,220...127,092,779
Ensembl chr 3:106,603,289...106,633,624
|
|
G |
Oat |
ornithine aminotransferase |
decreases expression |
EXP |
Irinotecan results in decreased expression of OAT mRNA |
CTD |
PMID:30012503 |
|
NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Ocln |
occludin |
decreases expression multiple interactions |
ISO |
Irinotecan results in decreased expression of OCLN protein GSK484 inhibits the reaction [Irinotecan results in decreased expression of OCLN protein]; phenethyl isothiocyanate inhibits the reaction [Irinotecan results in decreased expression of OCLN protein] |
CTD |
PMID:38341106 |
|
NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Ophn1 |
oligophrenin 1 |
increases expression |
ISO |
Irinotecan analog results in increased expression of OPHN1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr X:63,599,746...63,976,678
Ensembl chr X:63,603,042...63,976,633
|
|
G |
Orc1 |
origin recognition complex, subunit 1 |
increases response to substance |
ISO |
ORC1 protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 5:128,552,975...128,581,943
Ensembl chr 5:123,324,315...123,348,375
|
|
G |
Osmr |
oncostatin M receptor |
decreases response to substance increases expression |
ISO |
OSMR protein results in decreased susceptibility to Irinotecan Irinotecan metabolite results in increased expression of OSMR mRNA; Irinotecan results in increased expression of OSMR mRNA |
CTD |
PMID:15956246 PMID:16734730 |
|
NCBI chr 2:55,907,119...55,961,373
Ensembl chr 2:55,907,132...55,961,262
|
|
G |
Pag1 |
phosphoprotein membrane anchor with glycosphingolipid microdomains 1 |
increases expression |
ISO |
Irinotecan analog results in increased expression of PAG1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:93,842,747...93,984,314
Ensembl chr 2:92,057,216...92,069,849
|
|
G |
Pam |
peptidylglycine alpha-amidating monooxygenase |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PAM mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 9:105,445,812...105,719,287
Ensembl chr 9:98,122,916...98,271,965
|
|
G |
Pan3 |
poly(A) specific ribonuclease subunit PAN3 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PAN3 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr12:7,476,707...7,595,384
Ensembl chr12:7,476,697...7,599,204
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases expression multiple interactions |
ISO |
Irinotecan results in increased expression of PARP1 protein rucaparib inhibits the reaction [Irinotecan results in increased expression of PARP1 protein] |
CTD |
PMID:30612311 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pawr |
pro-apoptotic WT1 regulator |
decreases expression |
ISO |
Irinotecan results in decreased expression of PAWR mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 7:45,531,480...45,611,492
Ensembl chr 7:43,645,084...43,725,028
|
|
G |
Pax5 |
paired box 5 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PAX5 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:63,554,784...63,741,380
Ensembl chr 5:58,765,036...58,944,326
|
|
G |
Pax7 |
paired box 7 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PAX7 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:157,279,623...157,381,188
Ensembl chr 5:151,999,092...152,097,979
|
|
G |
Pbxip1 |
PBX homeobox interacting protein 1 |
decreases response to substance |
ISO |
PBXIP1 protein results in decreased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 2:177,154,056...177,167,810
Ensembl chr 2:174,856,397...174,868,919
|
|
G |
Pcbd2 |
pterin-4 alpha-carbinolamine dehydratase 2 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PCBD2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr17:8,845,161...8,896,343
Ensembl chr17:8,845,084...8,910,539
|
|
G |
Pcdhgc3 |
protocadherin gamma subfamily C, 3 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of PCDHGC3 mRNA; Irinotecan results in increased expression of PCDHGC3 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr18:29,633,016...29,667,865
Ensembl chr18:29,493,954...29,667,868
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
affects expression |
EXP |
Irinotecan affects the expression of PCK1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pclaf |
PCNA clamp associated factor |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in decreased expression of PCLAF mRNA |
CTD |
PMID:16391804 |
|
NCBI chr 8:75,311,028...75,328,108
Ensembl chr 8:66,420,587...66,432,994 Ensembl chr 8:66,420,587...66,432,994
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
Irinotecan inhibits the reaction [nitrosobenzylmethylamine results in increased expression of PCNA protein] |
CTD |
PMID:15547733 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pde4b |
phosphodiesterase 4B |
decreases expression affects expression |
ISO EXP |
Irinotecan metabolite results in decreased expression of PDE4B mRNA; Irinotecan results in decreased expression of PDE4B mRNA Irinotecan affects the expression of PDE4B mRNA |
CTD |
PMID:15956246 PMID:20097248 |
|
NCBI chr 5:122,028,956...122,598,267
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Pdlim5 |
PDZ and LIM domain 5 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PDLIM5 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:233,625,478...233,793,582
Ensembl chr 2:230,952,248...231,120,275
|
|
G |
Pfdn2 |
prefoldin subunit 2 |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of PFDN2 mRNA |
CTD |
PMID:32812032 |
|
NCBI chr13:86,305,037...86,323,008
Ensembl chr13:83,753,877...83,790,504
|
|
G |
Pgm2l1 |
phosphoglucomutase 2-like 1 |
increases expression |
ISO |
Irinotecan analog results in increased expression of PGM2L1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:163,983,917...164,033,027
Ensembl chr 1:154,571,766...154,620,902
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PHLDA1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:48,853,690...48,855,894
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Phlda2 |
pleckstrin homology-like domain, family A, member 2 |
increases expression |
ISO |
Irinotecan results in increased expression of PHLDA2 mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 1:208,126,302...208,127,241
Ensembl chr 1:198,696,897...198,697,836
|
|
G |
Pigw |
phosphatidylinositol glycan anchor biosynthesis, class W |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PIGW mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:70,246,904...70,248,412
Ensembl chr10:69,748,789...69,790,475
|
|
G |
Pip5k1b |
phosphatidylinositol-4-phosphate 5-kinase type 1 beta |
affects expression |
EXP |
Irinotecan affects the expression of PIP5K1B mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 1:231,331,836...231,610,092
Ensembl chr 1:221,914,159...222,183,672
|
|
G |
Pkdcc |
protein kinase domain containing, cytoplasmic |
decreases expression |
ISO |
Irinotecan results in decreased expression of PKDCC mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 6:17,208,171...17,217,488
Ensembl chr 6:11,455,686...11,465,556
|
|
G |
Pla2g1b |
phospholipase A2 group IB |
affects expression |
EXP |
Irinotecan affects the expression of PLA2G1B mRNA |
CTD |
PMID:20097248 |
|
NCBI chr12:46,802,932...46,814,511
Ensembl chr12:41,142,200...41,153,226
|
|
G |
Pla2g2d |
phospholipase A2, group IID |
affects expression |
EXP |
Irinotecan affects the expression of PLA2G2D mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 5:156,299,374...156,305,816
Ensembl chr 5:151,018,870...151,022,525
|
|
G |
Plat |
plasminogen activator, tissue type |
increases expression decreases expression |
EXP ISO |
Irinotecan results in increased expression of PLAT mRNA Irinotecan analog results in decreased expression of PLAT mRNA |
CTD |
PMID:18927307 PMID:20097248 |
|
NCBI chr16:75,943,061...76,022,037
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions decreases secretion |
ISO |
[Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein Irinotecan results in decreased secretion of PLAU protein |
CTD |
PMID:36191607 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions |
ISO |
[Oleanolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; Irinotecan results in increased secretion of and results in decreased expression of PLAUR protein |
CTD |
PMID:36191607 |
|
NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Plcb1 |
phospholipase C beta 1 |
decreases expression |
EXP |
Irinotecan results in decreased expression of PLCB1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Plcxd2 |
phosphatidylinositol-specific phospholipase C, X domain containing 2 |
increases expression |
ISO |
Irinotecan analog results in increased expression of PLCXD2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr11:68,263,626...68,315,962
Ensembl chr11:54,789,477...54,853,344
|
|
G |
Pld1 |
phospholipase D1 |
affects expression |
EXP |
Irinotecan affects the expression of PLD1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 2:112,777,820...112,975,857
Ensembl chr 2:110,893,608...111,047,692
|
|
G |
Plekha5 |
pleckstrin homology domain containing A5 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PLEKHA5 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:175,065,011...175,234,672
Ensembl chr 4:173,334,055...173,503,546
|
|
G |
Plekhh3 |
pleckstrin homology, MyTH4 and FERM domain containing H3 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of PLEKHH3 mRNA; Irinotecan results in increased expression of PLEKHH3 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr10:86,098,461...86,106,931
Ensembl chr10:86,098,469...86,106,880
|
|
G |
Plk1 |
polo-like kinase 1 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of PLK1 mRNA; Irinotecan results in decreased expression of PLK1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 1:186,147,658...186,157,637
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of PLK2 mRNA; Irinotecan results in increased expression of PLK2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 2:43,702,536...43,708,305
Ensembl chr 2:41,969,176...41,974,947
|
|
G |
Plk3 |
polo-like kinase 3 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of PLK3 mRNA; Irinotecan results in increased expression of PLK3 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 5:135,843,725...135,848,900
Ensembl chr 5:130,607,142...130,612,317
|
|
G |
Plpp1 |
phospholipid phosphatase 1 |
decreases response to substance |
ISO |
PLPP1 protein results in decreased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 2:46,172,202...46,233,632
Ensembl chr 2:44,438,994...44,501,268
|
|
G |
Plrg1 |
pleiotropic regulator 1 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in increased expression of PLRG1 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr 2:168,408,139...168,424,470
Ensembl chr 2:168,408,124...168,424,522
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of PMAIP1 mRNA; Irinotecan results in increased expression of PMAIP1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr18:62,255,970...62,262,384
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
affects expression |
EXP |
Irinotecan affects the expression of PMP22 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr10:48,294,932...48,324,941
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Pnrc1 |
proline-rich nuclear receptor coactivator 1 |
increases expression |
ISO |
Irinotecan analog results in increased expression of PNRC1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:52,443,400...52,489,303
Ensembl chr 5:47,647,071...47,650,161
|
|
G |
Pogz |
pogo transposable element derived with ZNF domain |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of POGZ mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:182,394,269...182,440,711
Ensembl chr 2:182,380,768...182,440,707
|
|
G |
Pola1 |
DNA polymerase alpha 1, catalytic subunit |
increases response to substance affects expression |
ISO EXP |
POLA1 protein results in increased susceptibility to Irinotecan Irinotecan affects the expression of POLA1 mRNA |
CTD |
PMID:16734730 PMID:20097248 |
|
NCBI chr X:62,028,475...62,342,455
Ensembl chr X:58,034,619...58,348,536
|
|
G |
Pole2 |
DNA polymerase epsilon 2, accessory subunit |
increases response to substance |
ISO |
POLE2 protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 6:93,410,713...93,448,782
Ensembl chr 6:87,674,702...87,699,305
|
|
G |
Polk |
DNA polymerase kappa |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of POLK mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:29,556,831...29,616,960
Ensembl chr 2:27,822,679...27,882,313
|
|
G |
Polr3g |
RNA polymerase III subunit G |
increases response to substance |
ISO |
POLR3G protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 2:13,680,893...13,721,802
Ensembl chr 2:11,945,217...11,986,125
|
|
G |
Pon3 |
paraoxonase 3 |
affects expression |
EXP |
Irinotecan affects the expression of PON3 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:34,323,546...34,350,244
Ensembl chr 4:33,349,168...33,383,855
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases response to substance |
ISO |
POR mRNA results in increased susceptibility to Irinotecan |
CTD |
PMID:15239142 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression multiple interactions |
ISO |
Irinotecan results in decreased expression of PPARG mRNA Luteolin inhibits the reaction [Irinotecan results in decreased expression of PPARG mRNA]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]]; PPARG protein affects the reaction [Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NFE2L2 mRNA]]; PPARG protein affects the reaction [Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]]; PPARG protein affects the reaction [Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]] |
CTD |
PMID:34699766 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppm1d |
protein phosphatase, Mg2+/Mn2+ dependent, 1D |
increases expression |
ISO |
Irinotecan analog results in increased expression of PPM1D mRNA |
CTD |
PMID:18927307 |
|
NCBI chr10:70,670,026...70,706,030
Ensembl chr10:70,172,603...70,208,607
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
decreases expression multiple interactions |
ISO |
Irinotecan analog results in decreased expression of PPP3CA mRNA [Fluorouracil co-treated with Irinotecan] results in increased expression of PPP3CA mRNA; PPP3CA protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] |
CTD |
PMID:16391804 PMID:18927307 |
|
NCBI chr 2:227,839,058...228,113,560
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Ppp3cb |
protein phosphatase 3 catalytic subunit beta |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of PPP3CB mRNA; Irinotecan results in decreased expression of PPP3CB mRNA |
CTD |
PMID:15956246 |
|
NCBI chr15:3,809,182...3,854,204
Ensembl chr15:3,760,030...3,804,981
|
|
G |
Ppp4r3b |
protein phosphatase 4, regulatory subunit 3B |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PPP4R3B mRNA |
CTD |
PMID:18927307 |
|
NCBI chr14:107,118,116...107,166,121
Ensembl chr14:102,917,443...103,068,192
|
|
G |
Prap1 |
proline-rich acidic protein 1 |
affects expression |
EXP |
Irinotecan affects the expression of PRAP1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 1:204,312,723...204,316,519
Ensembl chr 1:194,883,078...194,886,872
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PRKAA1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkca |
protein kinase C, alpha |
increases phosphorylation |
ISO |
Irinotecan metabolite results in increased phosphorylation of PRKCA protein; Irinotecan results in increased phosphorylation of PRKCA protein |
CTD |
PMID:15723263 |
|
NCBI chr10:93,388,991...93,787,617
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcb |
protein kinase C, beta |
increases phosphorylation |
ISO |
Irinotecan metabolite results in increased phosphorylation of PRKCB protein; Irinotecan results in increased phosphorylation of PRKCB protein |
CTD |
PMID:15723263 |
|
NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkcd |
protein kinase C, delta |
increases phosphorylation |
ISO |
Irinotecan metabolite results in increased phosphorylation of PRKCD protein; Irinotecan results in increased phosphorylation of PRKCD protein |
CTD |
PMID:15723263 |
|
NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkci |
protein kinase C, iota |
increases phosphorylation |
ISO |
Irinotecan metabolite results in increased phosphorylation of PRKCI protein; Irinotecan results in increased phosphorylation of PRKCI protein |
CTD |
PMID:15723263 |
|
NCBI chr 2:114,250,398...114,310,784
Ensembl chr 2:112,321,929...112,382,352
|
|
G |
Prkdc |
protein kinase, DNA-activated, catalytic subunit |
multiple interactions increases phosphorylation |
ISO |
IC486241 inhibits the reaction [Irinotecan results in increased phosphorylation of PRKDC protein] |
CTD |
PMID:17441964 PMID:21221710 |
|
NCBI chr11:98,544,952...98,762,499
Ensembl chr11:85,040,792...85,257,952
|
|
G |
Prlr |
prolactin receptor |
affects expression |
EXP |
Irinotecan affects the expression of PRLR mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 2:60,861,391...61,051,883
Ensembl chr 2:59,134,588...59,324,718
|
|
G |
Prom1 |
prominin 1 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of PROM1 mRNA; Irinotecan results in decreased expression of PROM1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr14:71,202,303...71,307,008
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Prr13 |
proline rich 13 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in increased expression of PRR13 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr 7:135,471,040...135,474,344
Ensembl chr 7:133,592,490...133,601,005
|
|
G |
Prr15 |
proline rich 15 |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of PRR15 mRNA |
CTD |
PMID:32812032 |
|
NCBI chr 4:83,432,002...83,435,582
Ensembl chr 4:83,431,758...83,437,436
|
|
G |
Prss12 |
serine protease 12 |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of PRSS12 mRNA |
CTD |
PMID:32812032 |
|
NCBI chr 2:214,308,695...214,368,679
Ensembl chr 2:211,624,134...211,684,126
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
increases response to substance |
ISO |
PSAT1 protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 1:222,623,553...222,646,187
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Ptch1 |
patched 1 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in increased expression of PTCH1 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333
|
|
G |
Ptges |
prostaglandin E synthase |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of PTGES mRNA; Irinotecan results in increased expression of PTGES mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 3:34,575,643...34,586,987
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Irinotecan results in increased expression of PTGS2 protein carvacrol inhibits the reaction [Irinotecan results in increased expression of PTGS2 protein] |
CTD |
PMID:27838229 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PTK2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:107,015,730...107,220,865
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ptp4a1 |
protein tyrosine phosphatase 4A1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PTP4A1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 9:40,710,250...40,718,176
Ensembl chr 9:33,214,208...33,221,964
|
|
G |
Ptpn13 |
protein tyrosine phosphatase, non-receptor type 13 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of PTPN13 mRNA; Irinotecan results in decreased expression of PTPN13 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr14:6,108,202...6,282,619
Ensembl chr14:6,108,211...6,282,563
|
|
G |
Ptpn22 |
protein tyrosine phosphatase, non-receptor type 22 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of PTPN22 mRNA; Irinotecan results in increased expression of PTPN22 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 2:194,055,165...194,103,209
Ensembl chr 2:191,366,808...191,414,779
|
|
G |
Ptprd |
protein tyrosine phosphatase, receptor type, D |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of PTPRD mRNA; Irinotecan results in increased expression of PTPRD mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 5:90,046,993...90,698,977 NCBI chr 5:91,122,354...91,641,754
Ensembl chr 5:90,048,966...92,369,396
|
|
G |
Ptprg |
protein tyrosine phosphatase, receptor type, G |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of PTPRG mRNA |
CTD |
PMID:18927307 |
|
NCBI chr15:12,871,706...13,552,186
Ensembl chr15:12,871,721...13,554,094
|
|
G |
Ptprn |
protein tyrosine phosphatase, receptor type, N |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of PTPRN mRNA; Irinotecan results in increased expression of PTPRN mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 9:84,189,676...84,205,364
Ensembl chr 9:76,741,016...76,756,190
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
affects expression |
EXP |
Irinotecan affects the expression of PTTG1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr10:28,394,940...28,406,410
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Rab27a |
RAB27A, member RAS oncogene family |
affects expression |
EXP |
Irinotecan affects the expression of RAB27A mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 8:82,663,373...82,717,267
Ensembl chr 8:73,782,694...73,847,829
|
|
G |
Rab31 |
RAB31, member RAS oncogene family |
decreases response to substance |
ISO |
RAB31 protein results in decreased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 9:112,693,596...112,828,104
Ensembl chr 9:105,246,709...105,381,253
|
|
G |
Rac3 |
Rac family small GTPase 3 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of RAC3 mRNA; Irinotecan results in increased expression of RAC3 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr10:106,002,808...106,005,243
Ensembl chr10:105,993,087...106,005,260
|
|
G |
Rad23b |
RAD23 homolog B, nucleotide excision repair protein |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of RAD23B mRNA; Irinotecan results in decreased expression of RAD23B mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 5:74,885,518...74,923,621
Ensembl chr 5:70,090,232...70,128,319
|
|
G |
Rad51 |
RAD51 recombinase |
increases expression multiple interactions |
ISO |
Irinotecan results in increased expression of RAD51 protein [Irinotecan co-treated with 2-(morpholin-4-yl)benzo(h)chromen-4-one] results in increased expression of RAD51 protein; [Irinotecan co-treated with IC486241] results in increased expression of RAD51 protein |
CTD |
PMID:21221710 |
|
NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Ramp1 |
receptor activity modifying protein 1 |
affects expression |
EXP |
Irinotecan affects the expression of RAMP1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 9:91,765,481...91,816,152
Ensembl chr 9:91,781,285...91,816,151
|
|
G |
Rarres1 |
retinoic acid receptor responder 1 |
increases expression |
EXP |
Irinotecan results in increased expression of RARRES1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 2:154,059,761...154,094,021
Ensembl chr 2:151,749,715...151,783,978
|
|
G |
Rasa1 |
RAS p21 protein activator 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of RASA1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:17,593,136...17,676,707
Ensembl chr 2:15,857,980...15,940,854
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
affects expression |
ISO |
Irinotecan affects the expression of RB1 protein |
CTD |
PMID:15132777 |
|
NCBI chr15:54,780,858...54,911,989
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbbp5 |
RB binding protein 5, histone lysine methyltransferase complex subunit |
decreases expression increases expression |
ISO |
Irinotecan metabolite results in decreased expression of RBBP5 mRNA; Irinotecan results in decreased expression of RBBP5 mRNA Irinotecan metabolite results in increased expression of RBBP5 mRNA; Irinotecan results in increased expression of RBBP5 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr13:46,464,389...46,494,244
Ensembl chr13:43,912,254...43,939,107
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of RBL1 mRNA; Irinotecan results in decreased expression of RBL1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 3:166,226,187...166,289,862
Ensembl chr 3:145,807,095...145,869,330
|
|
G |
Rbm24 |
RNA binding motif protein 24 |
increases expression |
ISO |
Irinotecan analog results in increased expression of RBM24 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr17:18,481,893...18,494,440
Ensembl chr17:18,275,688...18,288,102
|
|
G |
Rbms1 |
RNA binding motif, single stranded interacting protein 1 |
decreases response to substance |
ISO |
RBMS1 protein results in decreased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 3:65,604,475...65,829,072
Ensembl chr 3:45,197,972...45,420,376
|
|
G |
Rbp2 |
retinol binding protein 2 |
affects expression |
EXP |
Irinotecan affects the expression of RBP2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 8:107,958,670...107,983,850
Ensembl chr 8:99,079,104...99,104,473
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
multiple interactions decreases expression |
ISO |
[Fluorouracil co-treated with Irinotecan] results in decreased expression of RBPJ mRNA Irinotecan analog results in decreased expression of RBPJ mRNA |
CTD |
PMID:16391804 PMID:18927307 |
|
NCBI chr14:61,551,366...61,736,220
Ensembl chr14:57,338,507...57,523,353
|
|
G |
Reck |
reversion-inducing-cysteine-rich protein with kazal motifs |
increases expression |
ISO |
Irinotecan analog results in increased expression of RECK mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:62,898,717...62,965,274
Ensembl chr 5:58,102,981...58,169,502
|
|
G |
Reg1a |
regenerating family member 1 alpha |
affects expression |
EXP |
Irinotecan affects the expression of REG1A mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:112,450,466...112,453,130
Ensembl chr 4:110,892,453...110,895,570
|
|
G |
Reg3b |
regenerating family member 3 beta |
affects expression |
EXP |
Irinotecan affects the expression of REG3B mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:112,419,776...112,423,014
Ensembl chr 4:110,861,775...110,865,015
|
|
G |
Reg3g |
regenerating family member 3 gamma |
affects expression |
EXP |
Irinotecan affects the expression of REG3G mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:112,482,183...112,484,738
Ensembl chr 4:110,924,168...110,926,723
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases expression multiple interactions decreases response to substance increases activity |
EXP ISO |
Irinotecan results in increased expression of RELA protein [Irinotecan co-treated with Thalidomide co-treated with Celecoxib] results in increased expression of RELA protein; [Irinotecan co-treated with Thalidomide] results in increased expression of RELA protein RELA protein results in decreased susceptibility to Irinotecan Irinotecan results in increased activity of RELA protein |
CTD |
PMID:15161687 PMID:16685529 PMID:18182997 PMID:18535404 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Reps1 |
RALBP1 associated Eps domain containing 1 |
multiple interactions decreases expression |
ISO |
REPS1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] Irinotecan analog results in decreased expression of REPS1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:14,517,589...14,595,404
Ensembl chr 1:12,697,747...12,775,561
|
|
G |
Rfc3 |
replication factor C subunit 3 |
increases response to substance decreases expression |
ISO |
RFC3 protein results in increased susceptibility to Irinotecan Irinotecan metabolite results in decreased expression of RFC3 mRNA; Irinotecan results in decreased expression of RFC3 mRNA |
CTD |
PMID:15956246 PMID:16734730 |
|
NCBI chr12:5,836,546...5,847,331
Ensembl chr12:1,000,994...1,011,778
|
|
G |
Rgs1 |
regulator of G-protein signaling 1 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of RGS1 mRNA; Irinotecan results in increased expression of RGS1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr13:58,568,844...58,573,187
Ensembl chr13:56,018,554...56,022,984
|
|
G |
Rgs10 |
regulator of G-protein signaling 10 |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of RGS10 mRNA |
CTD |
PMID:32812032 |
|
NCBI chr 1:192,376,772...192,422,640
Ensembl chr 1:182,946,336...182,987,697
|
|
G |
Rgs22 |
regulator of G-protein signaling 22 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of RGS22 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:67,188,531...67,308,805
Ensembl chr 7:67,188,519...67,308,875
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
increases expression |
EXP |
Irinotecan results in increased expression of RGS4 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr13:84,469,593...84,475,884
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Rhob |
ras homolog family member B |
increases expression |
ISO |
Irinotecan results in increased expression of RHOB mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rhou |
ras homolog family member U |
increases expression |
ISO |
Irinotecan analog results in increased expression of RHOU mRNA |
CTD |
PMID:18927307 |
|
NCBI chr19:68,538,960...68,548,733
Ensembl chr19:51,641,227...51,650,552
|
|
G |
Rlim |
ring finger protein, LIM domain interacting |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of RLIM mRNA |
CTD |
PMID:18927307 |
|
NCBI chr X:68,983,259...69,004,368
Ensembl chr X:68,988,375...69,004,271
|
|
G |
Rnf34 |
ring finger protein 34 |
multiple interactions decreases response to substance |
ISO |
RNF34 protein inhibits the reaction [Irinotecan results in increased activity of CASP3 protein] RNF34 protein results in decreased susceptibility to Irinotecan |
CTD |
PMID:16080519 |
|
NCBI chr12:39,364,461...39,385,391
Ensembl chr12:33,703,673...33,724,586
|
|
G |
Rpl4 |
ribosomal protein L4 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of RPL4 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 8:73,566,477...73,571,600
Ensembl chr 8:64,671,160...64,676,306
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[Irinotecan co-treated with rucaparib] results in decreased expression of RPS6KB1 protein |
CTD |
PMID:30612311 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,323,777...71,367,908
|
|
G |
RT1-Db1 |
RT1 class II, locus Db1 |
increases expression |
ISO |
Irinotecan analog results in increased expression of HLA-DRB1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr20:4,550,594...4,560,182
Ensembl chr20:4,548,666...4,558,258
|
|
G |
Rtp4 |
receptor (chemosensory) transporter protein 4 |
affects expression |
EXP |
Irinotecan affects the expression of RTP4 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr11:90,741,992...90,840,061
Ensembl chr11:77,238,216...77,335,437
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of RUNX1 mRNA; Irinotecan results in decreased expression of RUNX1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr11:45,325,778...45,560,300
Ensembl chr11:31,843,764...32,074,542
|
|
G |
S100g |
S100 calcium binding protein G |
affects expression |
EXP |
Irinotecan affects the expression of S100G mRNA |
CTD |
PMID:20097248 |
|
NCBI chr X:35,337,636...35,340,205
Ensembl chr X:31,705,866...31,708,433
|
|
G |
Samd9 |
sterile alpha motif domain containing 9 |
increases expression |
ISO |
Irinotecan analog results in increased expression of SAMD9 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:32,119,318...32,139,008
Ensembl chr 4:31,164,510...31,184,322
|
|
G |
Samhd1 |
SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 |
affects expression |
ISO |
Irinotecan analog affects the expression of SAMHD1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 3:166,179,742...166,214,448
Ensembl chr 3:145,761,558...145,794,386
|
|
G |
Sat1 |
spermidine/spermine N1-acetyl transferase 1 |
decreases response to substance increases expression |
ISO |
SAT1 mRNA results in decreased susceptibility to Irinotecan Irinotecan results in increased expression of SAT1 mRNA |
CTD |
PMID:15152939 |
|
NCBI chr X:44,008,089...44,011,376
Ensembl chr X:40,157,046...40,196,813
|
|
G |
Scaf4 |
SR-related CTD-associated factor 4 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SCAF4 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr11:42,951,254...43,007,293
Ensembl chr11:29,465,106...29,521,153
|
|
G |
Scai |
suppressor of cancer cell invasion |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SCAI mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 3:43,222,983...43,335,056
Ensembl chr 3:22,819,574...22,925,363
|
|
G |
Scamp3 |
secretory carrier membrane protein 3 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in decreased expression of SCAMP3 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr 2:174,583,124...174,588,984
Ensembl chr 2:174,570,653...174,588,985
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
Irinotecan analog results in increased expression of SCD4 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Scin |
scinderin |
affects expression |
EXP |
Irinotecan affects the expression of SCIN mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 6:62,836,641...62,915,287
Ensembl chr 6:57,109,403...57,188,242
|
|
G |
Sdc4 |
syndecan 4 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of SDC4 mRNA; Irinotecan results in increased expression of SDC4 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 3:173,574,239...173,592,923
Ensembl chr 3:153,154,896...153,173,580
|
|
G |
Sec31a |
SEC31 homolog A, COPII coat complex component |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SEC31A mRNA |
CTD |
PMID:18927307 |
|
NCBI chr14:9,518,655...9,573,579
Ensembl chr14:9,214,349...9,269,273
|
|
G |
Sema3c |
semaphorin 3C |
increases expression |
ISO |
Irinotecan analog results in increased expression of SEMA3C mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:18,538,452...18,702,453
Ensembl chr 4:17,583,212...17,746,534
|
|
G |
Senp6 |
SUMO specific peptidase 6 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SENP6 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 8:80,988,675...81,071,606
Ensembl chr 8:80,989,052...81,067,170
|
|
G |
Serpinb5 |
serpin family B member 5 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in decreased expression of SERPINB5 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr13:23,500,203...23,520,401
Ensembl chr13:22,985,557...23,005,756
|
|
G |
Serpine2 |
serpin family E member 2 |
multiple interactions |
ISO |
SERPINE2 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] |
CTD |
PMID:17327601 |
|
NCBI chr 9:88,573,138...88,637,252
Ensembl chr 9:81,124,804...81,188,826
|
|
G |
Sertad1 |
SERTA domain containing 1 |
increases expression |
ISO |
Irinotecan results in increased expression of SERTAD1 mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 1:91,903,297...91,906,565
Ensembl chr 1:82,775,252...82,779,091
|
|
G |
Sesn2 |
sestrin 2 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of SESN2 mRNA; Irinotecan results in increased expression of SESN2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Setd1b |
SET domain containing 1B, histone lysine methyltransferase |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SETD1B mRNA |
CTD |
PMID:18927307 |
|
NCBI chr12:39,056,809...39,082,399
Ensembl chr12:33,396,120...33,426,934
|
|
G |
Setd5 |
SET domain containing 5 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SETD5 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 4:147,772,955...147,850,669
Ensembl chr 4:146,217,180...146,294,894
|
|
G |
Sfn |
stratifin |
multiple interactions |
ISO |
[Irinotecan co-treated with Bortezomib] results in decreased expression of SFN protein |
CTD |
PMID:16373703 |
|
NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
increases expression |
ISO |
Irinotecan analog results in increased expression of SGK1 mRNA; Irinotecan metabolite results in increased expression of SGK1 mRNA; Irinotecan results in increased expression of SGK1 mRNA |
CTD |
PMID:15956246 PMID:18927307 PMID:20185912 |
|
NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Sgo2 |
shugoshin 2 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SGO2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 9:59,548,605...59,573,229
Ensembl chr 9:59,548,683...59,573,229
|
|
G |
Siglec1 |
sialic acid binding Ig like lectin 1 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in increased expression of SIGLEC1 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr 3:138,740,171...138,759,966
Ensembl chr 3:118,287,988...118,306,850
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
increases response to substance |
ISO |
SKP2 protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 2:59,888,406...59,916,471
Ensembl chr 2:58,161,229...58,189,338
|
|
G |
Slc13a2 |
solute carrier family 13 member 2 |
affects expression |
EXP |
Irinotecan affects the expression of SLC13A2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr10:63,789,874...63,817,441
Ensembl chr10:63,291,815...63,319,127
|
|
G |
Slc16a4 |
solute carrier family 16, member 4 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of SLC16A4 mRNA; Irinotecan results in decreased expression of SLC16A4 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 2:194,911,075...194,933,162
Ensembl chr 2:194,911,236...194,933,117
|
|
G |
Slc19a1 |
solute carrier family 19 member 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SLC19A1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr20:11,583,928...11,601,959
Ensembl chr20:11,584,411...11,601,972
|
|
G |
Slc25a21 |
solute carrier family 25 member 21 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SLC25A21 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 6:74,203,439...74,702,902
Ensembl chr 6:74,203,440...74,702,680
|
|
G |
Slc25a36 |
solute carrier family 25 member 36 |
affects expression |
EXP |
Irinotecan affects the expression of SLC25A36 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 8:106,539,355...106,573,240
Ensembl chr 8:97,662,127...97,693,703
|
|
G |
Slc30a1 |
solute carrier family 30 member 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SLC30A1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr13:106,022,019...106,025,892
Ensembl chr13:103,491,037...103,494,910
|
|
G |
Slc31a1 |
solute carrier family 31 member 1 |
affects expression |
EXP |
Irinotecan affects the expression of SLC31A1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 5:80,830,574...80,859,810
Ensembl chr 5:75,814,743...75,844,228
|
|
G |
Slc39a4 |
solute carrier family 39 member 4 |
affects expression |
EXP |
Irinotecan affects the expression of SLC39A4 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 7:110,214,017...110,218,202
Ensembl chr 7:108,333,381...108,337,553
|
|
G |
Slc44a1 |
solute carrier family 44 member 1 |
affects expression |
EXP |
Irinotecan affects the expression of SLC44A1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 5:72,857,323...73,037,279
Ensembl chr 5:68,063,618...68,241,909
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Irinotecan inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue] |
CTD |
PMID:30863990 |
|
NCBI chr 1:163,371,410...163,419,412
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
affects expression |
EXP |
Irinotecan affects the expression of SLPI mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Smad3 |
SMAD family member 3 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SMAD3 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Smchd1 |
structural maintenance of chromosomes flexible hinge domain containing 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SMCHD1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 9:118,690,050...118,837,281
Ensembl chr 9:111,247,702...111,349,665
|
|
G |
Smu1 |
SMU1, DNA replication regulator and spliceosomal factor |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SMU1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:55,856,691...55,875,262
Ensembl chr 5:55,856,246...55,875,300
|
|
G |
Smurf1 |
SMAD specific E3 ubiquitin protein ligase 1 |
affects expression |
ISO |
Irinotecan analog affects the expression of SMURF1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr12:14,748,717...14,840,273
Ensembl chr12:9,635,025...9,726,519
|
|
G |
Snrpa1 |
small nuclear ribonucleoprotein polypeptide A' |
multiple interactions decreases expression |
ISO |
SNRPA1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] Irinotecan analog results in decreased expression of SNRPA1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:129,051,492...129,065,114
Ensembl chr 1:119,638,481...119,654,653
|
|
G |
Snrpf |
small nuclear ribonucleoprotein polypeptide F |
increases response to substance |
ISO |
SNRPF protein results in increased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 7:30,017,460...30,024,162
Ensembl chr 7:28,130,427...28,137,129
|
|
G |
Snx18 |
sorting nexin 18 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of SNX18 mRNA; Irinotecan results in decreased expression of SNX18 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 2:45,232,325...45,258,345
Ensembl chr 2:45,232,325...45,258,345
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases expression increases expression multiple interactions |
ISO |
Irinotecan results in decreased expression of SOD1 protein Irinotecan results in increased expression of SOD1 mRNA Luteolin inhibits the reaction [Irinotecan results in decreased expression of SOD1 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of SOD1 mRNA]; Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of SOD1 mRNA] |
CTD |
PMID:34699766 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
[Irinotecan co-treated with Fluorouracil] results in increased activity of SOD2 protein |
CTD |
PMID:15886469 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sp1 |
Sp1 transcription factor |
decreases expression multiple interactions increases phosphorylation |
ISO |
Irinotecan analog results in decreased expression of SP1 mRNA SP1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] Irinotecan results in increased phosphorylation of SP1 protein |
CTD |
PMID:17441964 PMID:18927307 |
|
NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sphk1 |
sphingosine kinase 1 |
affects expression |
EXP |
Irinotecan affects the expression of SPHK1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr10:102,257,413...102,263,086
Ensembl chr10:101,758,711...101,764,240
|
|
G |
Spib |
Spi-B transcription factor |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of SPIB mRNA; Irinotecan results in increased expression of SPIB mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 1:104,155,456...104,161,311
Ensembl chr 1:95,018,947...95,024,780
|
|
G |
Srp19 |
signal recognition particle 19 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in decreased expression of SRP19 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr18:26,205,888...26,212,171
Ensembl chr18:25,931,589...25,938,017
|
|
G |
Srpx |
sushi-repeat-containing protein, X-linked |
increases expression |
EXP |
Irinotecan results in increased expression of SRPX mRNA |
CTD |
PMID:20097248 |
|
NCBI chr X:12,676,984...12,751,296
Ensembl chr X:12,566,645...12,747,882
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
increases phosphorylation multiple interactions |
ISO |
Irinotecan results in increased phosphorylation of STAT1 protein STAT1 protein promotes the reaction [Irinotecan results in increased localization of FAS protein]; TP53 protein inhibits the reaction [Irinotecan results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:16204068 |
|
NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stk25 |
serine/threonine kinase 25 |
affects expression |
EXP |
Irinotecan affects the expression of STK25 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 9:94,161,834...94,174,095
Ensembl chr 9:94,161,836...94,174,244
|
|
G |
Stk38 |
serine/threonine kinase 38 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of STK38 mRNA; Irinotecan results in increased expression of STK38 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr20:7,035,923...7,070,657
Ensembl chr20:7,034,242...7,068,198
|
|
G |
Stk4 |
serine/threonine kinase 4 |
decreases expression multiple interactions |
ISO |
Irinotecan analog results in decreased expression of STK4 mRNA; Irinotecan metabolite results in decreased expression of STK4 mRNA; Irinotecan results in decreased expression of STK4 mRNA STK4 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] |
CTD |
PMID:15956246 PMID:18927307 |
|
NCBI chr 3:173,165,238...173,247,135
Ensembl chr 3:152,745,681...152,827,744
|
|
G |
Stx5 |
syntaxin 5 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in increased expression of STX5 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr 1:215,066,532...215,082,685
Ensembl chr 1:205,637,413...205,653,563
|
|
G |
Syde2 |
synapse defective Rho GTPase homolog 2 |
increases expression |
ISO |
Irinotecan analog results in increased expression of SYDE2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:234,897,975...234,930,994
Ensembl chr 2:234,897,717...234,930,994
|
|
G |
Syt1 |
synaptotagmin 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of SYT1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:45,699,649...46,244,460
Ensembl chr 7:43,815,785...44,357,803
|
|
G |
Taf2 |
TATA-box binding protein associated factor 2 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of TAF2 mRNA; Irinotecan results in decreased expression of TAF2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 7:88,312,374...88,369,399
Ensembl chr 7:86,422,613...86,479,616
|
|
G |
Taf5l1 |
TATA-box binding protein associated factor 5 like 1 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in decreased expression of TAF5L mRNA |
CTD |
PMID:16391804 |
|
NCBI chr19:68,889,153...68,908,480
Ensembl chr19:51,991,708...52,011,295
|
|
G |
Tardbp |
TAR DNA binding protein |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of TARDBP mRNA |
CTD |
PMID:32812032 |
|
NCBI chr 5:164,330,452...164,348,435
Ensembl chr 5:159,051,799...159,062,055
|
|
G |
Tbcc |
tubulin folding cofactor C |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of TBCC mRNA; Irinotecan results in increased expression of TBCC mRNA |
CTD |
PMID:15956246 PMID:20185912 |
|
NCBI chr 9:14,098,855...14,100,043
Ensembl chr 9:14,098,868...14,100,042
|
|
G |
Tcf12 |
transcription factor 12 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of TCF12 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 8:81,371,201...81,682,337
Ensembl chr 8:72,492,567...72,799,201
|
|
G |
Tcf7l2 |
transcription factor 7 like 2 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of TCF7L2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:264,791,335...264,984,225
Ensembl chr 1:254,786,091...254,978,967
|
|
G |
Tesk2 |
testis associated actin remodelling kinase 2 |
affects expression |
EXP |
Irinotecan affects the expression of TESK2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 5:130,178,715...130,270,594
Ensembl chr 5:130,185,033...130,271,292
|
|
G |
Tfcp2 |
transcription factor CP2 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of TFCP2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:133,495,577...133,537,799
Ensembl chr 7:131,616,785...131,658,939
|
|
G |
Tff1 |
trefoil factor 1 |
affects expression |
EXP |
Irinotecan affects the expression of TFF1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tff3 |
trefoil factor 3 |
affects expression |
EXP |
Irinotecan affects the expression of TFF3 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr20:9,194,623...9,199,333
Ensembl chr20:9,193,262...9,198,054
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of TFPI mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 3:89,939,862...89,989,253
Ensembl chr 3:69,533,156...69,576,880
|
|
G |
Tfrc |
transferrin receptor |
increases expression |
ISO |
Irinotecan analog results in increased expression of TFRC mRNA |
CTD |
PMID:18927307 |
|
NCBI chr11:81,668,478...81,690,318
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions decreases response to substance increases secretion |
ISO |
Gefitinib inhibits the reaction [Irinotecan metabolite results in increased secretion of TGFA protein]; Gefitinib inhibits the reaction [Irinotecan results in increased secretion of TGFA protein]; rottlerin inhibits the reaction [Irinotecan metabolite results in increased secretion of TGFA protein]; rottlerin inhibits the reaction [Irinotecan results in increased secretion of TGFA protein] TGFA protein results in decreased susceptibility to Irinotecan Irinotecan metabolite results in increased secretion of TGFA protein; Irinotecan results in increased secretion of TGFA protein |
CTD |
PMID:15723263 PMID:16734730 |
|
NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfbi |
transforming growth factor, beta induced |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of TGFBI mRNA |
CTD |
PMID:18927307 |
|
NCBI chr17:7,955,603...7,984,903
Ensembl chr17:7,955,603...7,985,240
|
|
G |
Thbs1 |
thrombospondin 1 |
decreases response to substance |
ISO |
THBS1 protein results in decreased susceptibility to Irinotecan |
CTD |
PMID:16734730 |
|
NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Thbs2 |
thrombospondin 2 |
increases expression |
EXP |
Irinotecan results in increased expression of THBS2 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 1:64,343,523...64,372,918
Ensembl chr 1:55,670,394...55,699,789
|
|
G |
Them4 |
thioesterase superfamily member 4 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of THEM4 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:184,642,603...184,663,752
Ensembl chr 2:181,953,550...181,974,708
|
|
G |
Thnsl1 |
threonine synthase-like 1 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of THNSL1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr17:88,623,054...88,630,681
Ensembl chr17:83,714,738...83,723,805
|
|
G |
Thrap3 |
thyroid hormone receptor associated protein 3 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of THRAP3 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:143,729,821...143,772,105
Ensembl chr 5:138,445,295...138,487,477
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of THY1 mRNA; Irinotecan results in increased expression of THY1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 8:53,286,396...53,291,541
Ensembl chr 8:44,389,513...44,394,659
|
|
G |
Tjp1 |
tight junction protein 1 |
decreases expression multiple interactions |
ISO |
Irinotecan results in decreased expression of TJP1 protein GSK484 inhibits the reaction [Irinotecan results in decreased expression of TJP1 protein]; phenethyl isothiocyanate inhibits the reaction [Irinotecan results in decreased expression of TJP1 protein] |
CTD |
PMID:38341106 |
|
NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tlr2 |
toll-like receptor 2 |
affects response to substance multiple interactions |
ISO |
TLR2 protein affects the susceptibility to Irinotecan TLR2 protein affects the reaction [Irinotecan affects the expression of IL1B mRNA]; TLR2 protein affects the reaction [Irinotecan affects the expression of NR1I2 mRNA]; TLR2 protein affects the reaction [Irinotecan affects the expression of NR1I3 mRNA]; TLR2 protein affects the reaction [Irinotecan affects the expression of TNF mRNA]; TLR2 protein affects the reaction [Irinotecan results in decreased expression of UGT1A1 mRNA]; TLR2 protein affects the reaction [Irinotecan results in increased expression of IL6 mRNA] |
CTD |
PMID:35728726 |
|
NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases expression multiple interactions affects response to substance |
ISO |
Irinotecan results in increased expression of TLR4 protein Silymarin inhibits the reaction [Irinotecan results in increased expression of TLR4 protein]; TLR4 protein affects the reaction [Irinotecan affects the expression of IL1B mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of NR1I2 mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of NR1I3 mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of TNF mRNA]; TLR4 protein affects the reaction [Irinotecan results in decreased expression of UGT1A1 mRNA]; TLR4 protein affects the reaction [Irinotecan results in increased expression of IL6 mRNA] TLR4 protein affects the susceptibility to Irinotecan |
CTD |
PMID:28454924 PMID:35728726 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tmem123 |
transmembrane protein 123 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of TMEM123 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 8:4,922,077...4,952,228
Ensembl chr 8:4,922,098...4,952,224
|
|
G |
Tmem267 |
transmembrane protein 267 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of TMEM267 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:51,580,210...51,588,937
Ensembl chr 2:51,581,252...51,587,636
|
|
G |
Tmem37 |
transmembrane protein 37 |
affects expression |
EXP |
Irinotecan affects the expression of TMEM37 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr13:31,184,322...31,191,477
Ensembl chr13:31,171,355...31,191,077
|
|
G |
Tmem41b |
transmembrane protein 41B |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of TMEM41B mRNA; Irinotecan results in decreased expression of TMEM41B mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 1:173,447,362...173,461,760
Ensembl chr 1:164,012,592...164,026,933
|
|
G |
Tmsb4x |
thymosin beta 4, X-linked |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of TMSB4X mRNA |
CTD |
PMID:32812032 |
|
NCBI chr X:30,761,611...30,763,612
Ensembl chr X:27,128,610...27,146,667 Ensembl chr10:27,128,610...27,146,667
|
|
G |
Tmt1b |
thiol methyltransferase 1B |
affects expression |
EXP |
Irinotecan affects the expression of TMT1B mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 7:1,388,876...1,391,526
Ensembl chr 7:1,388,879...1,391,526
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases secretion affects expression |
EXP ISO |
[Irinotecan co-treated with Ciprofloxacin] promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Ciprofloxacin inhibits the reaction [Irinotecan promotes the reaction [Mitogens results in increased expression of TNF protein]]; Irinotecan inhibits the reaction [Mitogens results in increased expression of TNF protein]; Irinotecan promotes the reaction [Mitogens results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of TNF protein] 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [carvacrol inhibits the reaction [Irinotecan results in increased expression of TNF protein]]; carvacrol inhibits the reaction [Irinotecan results in increased expression of TNF protein]; GSK484 inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]; MYD88 protein affects the reaction [Irinotecan affects the expression of TNF mRNA]; phenethyl isothiocyanate inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]; TLR2 protein affects the reaction [Irinotecan affects the expression of TNF mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of TNF mRNA] Irinotecan results in increased expression of TNF mRNA; Irinotecan results in increased expression of TNF protein Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]]; PPARG protein affects the reaction [Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]]; Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of TNF mRNA] Irinotecan results in increased secretion of TNF protein |
CTD |
PMID:16815871 PMID:18182997 PMID:18535404 PMID:19401694 PMID:26431797 PMID:27838229 PMID:34699766 PMID:35728726 PMID:38341106 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of TNFAIP6 mRNA; Irinotecan results in decreased expression of TNFAIP6 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 3:56,911,398...56,930,797
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf12a |
TNF receptor superfamily member 12A |
increases expression |
EXP |
Irinotecan results in increased expression of TNFRSF12A mRNA |
CTD |
PMID:20097248 |
|
NCBI chr10:13,211,670...13,213,666
Ensembl chr10:12,689,890...12,709,045
|
|
G |
Tnfrsf14 |
TNF receptor superfamily member 14 |
affects expression |
EXP |
Irinotecan affects the expression of TNFRSF14 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 5:170,768,413...170,776,749
Ensembl chr 5:165,484,262...165,493,703
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
EXP |
Irinotecan results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions increases activity |
ISO |
CFLAR protein alternative form inhibits the reaction [Irinotecan results in increased activity of TNFSF10 protein] |
CTD |
PMID:16373718 |
|
NCBI chr 2:112,136,550...112,155,903
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tob1 |
transducer of ErbB-2.1 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of TOB1 mRNA; Irinotecan results in increased expression of TOB1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr10:79,659,993...79,662,031
Ensembl chr10:79,160,154...79,165,215
|
|
G |
Tob2 |
transducer of ERBB2, 2 |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of TOB2 mRNA; Irinotecan results in increased expression of TOB2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 7:115,242,843...115,251,563
Ensembl chr 7:113,361,148...113,372,688
|
|
G |
Top1 |
DNA topoisomerase I |
decreases activity affects binding affects response to substance |
ISO |
Irinotecan results in decreased activity of TOP1 protein Irinotecan binds to TOP1 protein TOP1 protein affects the susceptibility to Irinotecan |
CTD |
PMID:11914913 PMID:15041737 PMID:15655543 PMID:18509181 |
|
NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Top2a |
DNA topoisomerase II alpha |
increases response to substance decreases expression |
ISO |
TOP2A mRNA results in increased susceptibility to Irinotecan Irinotecan metabolite results in decreased expression of TOP2A mRNA; Irinotecan results in decreased expression of TOP2A mRNA |
CTD |
PMID:15239142 PMID:15956246 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Top6bl |
TOP6B like initiator of meiotic double strand breaks |
increases expression |
ISO |
Irinotecan analog results in increased expression of TOP6BL mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:211,331,973...211,419,015
|
|
G |
Topors |
TOP1 binding arginine/serine rich protein, E3 ubiquitin ligase |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of TOPORS mRNA; Irinotecan results in decreased expression of TOPORS mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 5:60,184,076...60,195,979
Ensembl chr 5:55,387,632...55,399,937
|
|
G |
Tp53 |
tumor protein p53 |
increases expression increases response to substance multiple interactions increases phosphorylation affects response to substance affects activity |
ISO |
Irinotecan results in increased expression of TP53 mRNA; Irinotecan results in increased expression of TP53 protein TP53 results in increased susceptibility to Irinotecan [Irinotecan co-treated with Bortezomib] results in increased ubiquitination of TP53 protein; Irinotecan results in increased phosphorylation of and results in increased activity of TP53 protein; Irinotecan results in increased phosphorylation of and results in increased expression of TP53 protein; TP53 protein affects the susceptibility to [Irinotecan co-treated with Bortezomib]; TP53 protein inhibits the reaction [Irinotecan results in increased phosphorylation of STAT1 protein] Irinotecan results in increased phosphorylation of TP53 protein TP53 protein affects the susceptibility to Irinotecan Irinotecan affects the activity of TP53 protein; Irinotecan metabolite affects the activity of TP53 protein |
CTD |
PMID:16204068 PMID:16373703 PMID:16963839 PMID:22510560 PMID:22898888 PMID:35435491 More...
|
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53inp1 |
tumor protein p53 inducible nuclear protein 1 |
increases expression |
ISO |
Irinotecan analog results in increased expression of TP53INP1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:29,051,267...29,069,486
Ensembl chr 5:24,260,568...24,267,968
|
|
G |
Tpmt |
thiopurine S-methyltransferase |
increases expression multiple interactions |
ISO |
Irinotecan analog results in increased expression of TPMT mRNA TPMT protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] |
CTD |
PMID:18927307 |
|
NCBI chr17:17,850,308...17,868,976
Ensembl chr17:17,644,173...17,662,709
|
|
G |
Tppp |
tubulin polymerization promoting protein |
increases expression |
ISO |
Irinotecan analog results in increased expression of TPPP mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 1:31,085,680...31,109,703
Ensembl chr 1:29,261,255...29,281,134
|
|
G |
Tpx2 |
TPX2, microtubule nucleation factor |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of TPX2 mRNA; Irinotecan results in decreased expression of TPX2 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
increases expression |
ISO |
Irinotecan metabolite results in increased expression of TRADD mRNA; Irinotecan results in increased expression of TRADD mRNA |
CTD |
PMID:15956246 |
|
NCBI chr19:50,046,057...50,048,158
Ensembl chr19:33,136,138...33,142,638
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
decreases expression increases expression |
ISO |
Irinotecan metabolite results in decreased expression of TRAF1 mRNA; Irinotecan results in decreased expression of TRAF1 mRNA Irinotecan metabolite results in increased expression of TRAF1 mRNA; Irinotecan results in increased expression of TRAF1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 3:38,607,707...38,639,641
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Trdmt1 |
tRNA aspartic acid methyltransferase 1 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of TRDMT1 mRNA; Irinotecan results in decreased expression of TRDMT1 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr17:81,510,740...81,554,036
Ensembl chr17:76,610,543...76,645,439
|
|
G |
Trib1 |
tribbles pseudokinase 1 |
increases expression |
ISO |
Irinotecan analog results in increased expression of TRIB1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 7:93,096,001...93,102,547
Ensembl chr 7:91,206,579...91,214,731
|
|
G |
Trib2 |
tribbles pseudokinase 2 |
affects expression |
ISO |
Irinotecan analog affects the expression of TRIB2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370
|
|
G |
Trim9 |
tripartite motif-containing 9 |
increases expression |
ISO |
Irinotecan analog results in increased expression of TRIM9 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 6:88,756,824...88,856,588
Ensembl chr 6:88,757,303...88,856,542
|
|
G |
Trmt13 |
tRNA methyltransferase 13 homolog |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of TRMT13 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 2:204,533,630...204,547,711
Ensembl chr 2:204,533,632...204,546,843
|
|
G |
Tsen2 |
tRNA splicing endonuclease subunit 2 |
decreases expression |
ISO |
Irinotecan results in decreased expression of TSEN2 mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 4:150,275,389...150,310,846
Ensembl chr 4:148,602,863...148,638,215
|
|
G |
Tspan4 |
tetraspanin 4 |
increases expression |
EXP |
Irinotecan results in increased expression of TSPAN4 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 1:206,001,731...206,021,414
Ensembl chr 1:196,572,228...196,617,448
|
|
G |
Tspan8 |
tetraspanin 8 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in decreased expression of TSPAN8 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr 7:51,444,946...51,479,360
Ensembl chr 7:51,445,074...51,479,356
|
|
G |
Ttk |
Ttk protein kinase |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of TTK mRNA; Irinotecan results in decreased expression of TTK mRNA |
CTD |
PMID:15956246 |
|
NCBI chr 8:93,632,678...93,672,664
Ensembl chr 8:84,754,315...84,792,651
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression |
ISO |
Irinotecan results in increased expression of TXNIP mRNA |
CTD |
PMID:20185912 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
affects expression |
EXP |
Irinotecan affects the expression of TXNRD1 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Tymp |
thymidine phosphorylase |
multiple interactions |
ISO |
TYMP mRNA affects the susceptibility to [Irinotecan co-treated with Fluorouracil co-treated with Leucovorin] |
CTD |
PMID:17454858 |
|
NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
G |
Tyms |
thymidylate synthetase |
multiple interactions |
ISO |
TYMS mRNA affects the susceptibility to [Irinotecan co-treated with Fluorouracil co-treated with Leucovorin] |
CTD |
PMID:17454858 |
|
NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Tyrobp |
transmembrane immune signaling adaptor Tyrobp |
multiple interactions |
ISO |
[PHY 906 co-treated with Irinotecan] affects the expression of TYROBP mRNA |
CTD |
PMID:32812032 |
|
NCBI chr 1:94,800,372...94,804,307
Ensembl chr 1:85,672,994...85,676,848
|
|
G |
Ubd |
ubiquitin D |
affects expression |
EXP |
Irinotecan affects the expression of UBD mRNA |
CTD |
PMID:20097248 |
|
NCBI chr20:1,390,734...1,392,685
Ensembl chr20:1,385,864...1,408,639 Ensembl chr20:1,385,864...1,408,639
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
decreases expression |
ISO EXP |
Irinotecan metabolite results in decreased expression of UBE2C mRNA; Irinotecan results in decreased expression of UBE2C mRNA |
CTD |
PMID:15956246 PMID:20097248 |
|
NCBI chr 3:173,925,975...173,928,375
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Ube2e3 |
ubiquitin-conjugating enzyme E2E 3 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of UBE2E3 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 3:63,786,976...63,851,400
Ensembl chr 3:63,786,650...63,843,237
|
|
G |
Ube2j2 |
ubiquitin-conjugating enzyme E2, J2 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of UBE2J2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:171,815,607...171,830,037
Ensembl chr 5:166,533,418...166,547,804
|
|
G |
Ube2l6 |
ubiquitin-conjugating enzyme E2L 6 |
affects expression |
EXP |
Irinotecan affects the expression of UBE2L6 mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 3:90,279,705...90,294,721
Ensembl chr 3:69,873,424...69,888,048
|
|
G |
Uchl5 |
ubiquitin C-terminal hydrolase L5 |
decreases expression |
ISO |
Irinotecan metabolite results in decreased expression of UCHL5 mRNA; Irinotecan results in decreased expression of UCHL5 mRNA |
CTD |
PMID:15956246 |
|
NCBI chr13:58,070,947...58,106,825
Ensembl chr13:55,520,729...55,556,502
|
|
G |
Uggt2 |
UDP-glucose glycoprotein glucosyltransferase 2 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of UGGT2 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr15:96,074,557...96,239,365
Ensembl chr15:96,074,564...96,237,806
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
affects response to substance multiple interactions increases glucuronidation affects metabolic processing increases metabolic processing decreases glucuronidation decreases activity decreases expression affects glucuronidation |
ISO EXP |
UGT1A1 gene polymorphism affects the susceptibility to Irinotecan; UGT1A1 promoter polymorphism affects the susceptibility to Irinotecan; UGT1A1 protein affects the susceptibility to Irinotecan [Ketoconazole results in decreased activity of UGT1A1 protein] which results in decreased metabolism of Irinotecan; [UGT1A1 protein mutant form affects the glucuronidation of Irinotecan] which results in decreased abundance of 7-ethyl-10-hydroxycamptothecin beta-glucuronide; [UGT1A1 protein results in increased glucuronidation of Irinotecan] which results in increased abundance of 7-ethyl-10-hydroxycamptothecin beta-glucuronide; UGT1A1 gene polymorphism affects the susceptibility to [Fluorouracil co-treated with Irinotecan]; UGT1A1 protein results in increased glucuronidation of and results in decreased activity of Irinotecan UGT1A1 protein affects the metabolism of Irinotecan UGT1A1 protein results in increased metabolism of Irinotecan UGT1A1 gene mutant form results in decreased glucuronidation of Irinotecan; UGT1A1 protein polymorphism results in decreased glucuronidation of Irinotecan Irinotecan results in decreased activity of UGT1A1 protein MYD88 protein affects the reaction [Irinotecan results in decreased expression of UGT1A1 mRNA]; TLR2 protein affects the reaction [Irinotecan results in decreased expression of UGT1A1 mRNA]; TLR4 protein affects the reaction [Irinotecan results in decreased expression of UGT1A1 mRNA] |
CTD |
PMID:12960109 PMID:15517893 PMID:15523087 PMID:15655543 PMID:15716465 PMID:15833930 PMID:15858133 PMID:17898154 PMID:18300238 PMID:18478930 PMID:18797458 PMID:22447115 PMID:23401472 PMID:35728726 PMID:35930428 More...
|
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
increases glucuronidation |
ISO |
UGT1A6 protein results in increased glucuronidation of Irinotecan |
CTD |
PMID:15716465 PMID:35930428 |
|
NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a7c |
UDP glucuronosyltransferase 1 family, polypeptide A7C |
increases glucuronidation |
EXP |
UGT1A7 protein results in increased glucuronidation of Irinotecan |
CTD |
PMID:15833930 |
|
NCBI chr 9:96,187,382...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a8 |
UDP glucuronosyltransferase family 1 member A8 |
increases glucuronidation |
EXP |
UGT1A8 protein results in increased glucuronidation of Irinotecan |
CTD |
PMID:15833930 |
|
NCBI chr 9:88,727,094...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation multiple interactions affects glucuronidation |
ISO EXP |
UGT1A9 protein results in increased glucuronidation of Irinotecan [UGT1A9 protein mutant form affects the glucuronidation of Irinotecan] which results in decreased abundance of 7-ethyl-10-hydroxycamptothecin beta-glucuronide |
CTD |
PMID:15833930 PMID:17898154 PMID:35930428 |
|
NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ulk4 |
unc-51 like kinase 4 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of ULK4 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 8:129,548,431...129,843,555
Ensembl chr 8:120,670,866...120,966,924
|
|
G |
Uso1 |
USO1 vesicle transport factor |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of USO1 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr14:16,150,921...16,216,389
Ensembl chr14:15,866,638...15,932,171
|
|
G |
Usp24 |
ubiquitin specific peptidase 24 |
decreases expression |
ISO |
Irinotecan analog results in decreased expression of USP24 mRNA |
CTD |
PMID:18927307 |
|
NCBI chr 5:126,309,396...126,439,147
Ensembl chr 5:121,080,470...121,210,311
|
|
G |
Utp3 |
UTP3, small subunit processome component |
multiple interactions |
ISO |
[Fluorouracil co-treated with Irinotecan] results in increased expression of UTP3 mRNA |
CTD |
PMID:16391804 |
|
NCBI chr14:19,799,766...19,801,420
Ensembl chr14:19,515,669...19,517,396
|
|
G |
Vldlr |
very low density lipoprotein receptor |
affects expression |
EXP |
Irinotecan affects the expression of VLDLR mRNA |
CTD |
PMID:20097248 |
|
NCBI chr 1:234,239,769...234,272,150
Ensembl chr 1:224,814,377...224,845,920
|
|
G |
Vps13b |
vacuolar protein sorting 13 homolog B |
decreases expression |
EXP |
Irinotecan results in de | |